Psychedelics and the Human Receptorome Authors: Thomas S. Ray Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0009019 ABSTRACT We currently understand the mental effects of psychedelics to be caused by agonism or partial agonism of 5-HT 2A (and possibly 5-HT 2C ) receptors, and we understand that psychedelic drugs, especially phenylalkylamines, are fairly selective for these two receptors. This manuscript is a reference work on the receptor affinity pharmacology of psychedelic drugs. New data is presented on the affinity of twenty-five psychedelic drugs at fifty-one receptors, transporters, and ion channels, assayed by the National Institute of Mental Health – Psychoactive Drug Screening Program (NIMH-PDSP). In addition, comparable data gathered from the literature on ten additional drugs is also presented (mostly assayed by the NIMH-PDSP). A new method is introduced for normalizing affinity (K i ) data that factors out potency so that the multi-receptor affinity profiles of different drugs can be directly compared and contrasted. The method is then used to compare the thirty-five drugs in graphical and tabular form. It is shown that psychedelic drugs, especially phenylalkylamines, are not as selective as generally believed, interacting with forty-two of forty-nine broadly assayed sites. The thirty-five drugs of the study have very diverse patterns of interaction with different classes of receptors, emphasizing eighteen different receptors. This diversity of receptor interaction may underlie the qualitative diversity of these drugs. It should be possible to use this diverse set of drugs as probes into the roles played by the various receptor systems in the human mind. INTRODUCTION We currently understand the mental effects of psychedelics to be caused by agonism or partial agonism of 5-HT 2A (and possibly 5-HT 2C ) receptors (serotonin-2A and serotonin-2C receptors) [1] . This understanding was first developed in the 1980s [2] – [4] and has since been confirmed by a large body of evidence, as reviewed recently by Nichols [1] . However, many authors have commented that other receptors may also play a role [1] , [3] , [5] – [9] . In this post-genome era of high-throughput assays, it is time to take a broader view, move beyond the common-denominator approach [6] , and begin to explore the role of other receptors in shaping the mental effects of psychedelics, especially the qualitative differences among them. The objective of this paper is to present the receptor binding profiles of the thirty-five drugs ( Fig. 1 , Fig. 2 ) of this study in such a way that they can be easily compared in both their similarities and their differences. This is intended to serve as a reference work on the multi-receptor affinity pharmacology of psychedelic drugs. The tables and figures are the heart of this manuscript. Some of them have been included as “supporting information,” because they exceed the size limits of standard tables and figures. However, this supporting information is no less central to the manuscript than the standard tables and figures. Twenty-five drugs assayed for this study by the NIMH-PDPS against fifty-one receptors, transporters and ion-channels. The twenty-five drugs include sixteen phenylalkylamines, eight tryptamines, and one ergoline. The three control drugs on the right include one representative from each structural class, and are believed to be non-psychedelic. Ten drugs whose receptor profiles were collected from the literature. All but ibogaine, THC, and morphine were assayed by the NIMH-PDSP. METHODS Data on receptor interactions of ten compounds ( Fig. 2 ) has been collected from the literature. The four ergolines (LSD, cis-2a, RR-2b, and SS-2c) were assayed by NIMH-PDSP against forty-three receptors, transporters and ion channels [10] . Salvinorin A was assayed by NIMH-PDSP against thirty receptors and transporters [11] . EMDT and 5-MeO-TMT were assayed by NIMH-PDSP against forty receptors, transporters and ion channels [12] . Receptor data for ibogaine ( Table S1 ), morphine ( Table 1 ) and THC ( Table 2 ) was collected from a variety of sources. While ibogaine has been assayed at a wide variety of receptors, morphine and THC have not, so their data should be used with caution. Although morphine is not considered to be a psychedelic, and ibogaine, THC, and salvinorin A are not considered to be “classical hallucinogens,” these four compounds are included because they provide insights into additional receptor systems (salvinorin A – κ (kappa opioid receptor), ibogaine – σ (sigma receptor) and κ, THC – CB (cannabinoid receptor), morphine – μ (mu opioid receptor)). These additional compounds could also be thought of as active controls, as compared to the three presumably inactive controls of Fig. 1 . Receptor affinity data for morphine collected from the literature. The columns identify the receptor, the radioligand used in determining affinity, the source species from which the receptor was used, the tissue from which the receptor was used, the K i value in nanomoles or the IC50 (the molar concentration of an unlabeled agonist or antagonist that inhibits the binding of a radioligand by 50%, [26] ) value in nanomoles, and the literature reference from which the data was obtained. Receptor affinity data for THC collected from the literature. The columns identify the receptor, the radioligand used in determining affinity, the source species from which the receptor was used, the tissue from which the receptor was used, the K i value in nanomoles, and the literature reference from which the data was obtained. TABLE: Receptor affinity data for morphine. Receptors Hot Ligand Source Tissue Ki(nM) IC50(nM) Reference KOR 3H-U69,593 GUINEA PIG ILEUM 217±49 PDSP; [17] 3H-U69,593 Human cloned 134±22 PDSP; [18] [Dmt]DALDA Human cloned 4.4±1.7 [19] DMAGO Human cloned 213±28 [19] [3H]U69593 rat Brain 113±9 PDSP; [20] 50 average human MOR 3H-DAMGO GUINEA PIG ILEUM 1±0.04 PDSP; [17] 3H-Diprenorphine Human cloned 2.06±0.48 PDSP; [18] 3H-Dmt-DALDA mouse Brain 5.64±0.24 PDSP; [19] [Dmt]DALDA human cloned 0.172±0.026 [19] DMAGO human cloned 1.180±0.120 [19] [3H]DAMGO rat Brain 6.55±0.74 PDSP; [20] HEK-μ cells 2.2±0.5 [21] [3H]DAMGO human BE(2)-C memberanes 1.02±0.15 PDSP; [22] bovine adrenals 1.86 [23] 0.81 average human DOR 3H-DSLET MOUSE vas deferens 32.6±3.7 PDSP; [17] 3H-Naltrindole Human cloned >10,000 PDSP; [18] [Dmt]DALDA human cloned 1670±40 [19] DMAGO human cloned 1430±20 [19] [3H][Ile5,6]deltorphin II rat Brain 217±19 PDSP; [20] 278±49 [24] [3H]DPDPE human BE(2)-C memberanes >100 PDSP; [22] [3H]enkephalin rat memberane 69.1±3.2 [25] bovine adrenals 147.32 [23] 1545 average human TABLE: Receptor affinity data for THC. Receptors hot ligand source tissue Ki(nM) Ref CB1 3H-BAY 38-7271 HUMAN CORTICAL MEMBRANES 13.7 PDSP; [27] 3H-BAY 38-7271 HUMAN CLONED 15.3 PDSP; [28] 3H-CP-55940 HUMAN CLONED 5.05 PDSP; [29] 10.19 average CB2 3H-BAY 38-7271 HUMAN CLONED 25.06 PDSP; [28] 3H-BAY 38-7271 HUMAN CLONED 22.9 PDSP; [27] 3H-CP-55940 HUMAN CLONED 44.9 [30] 3H-CP-55940 HUMAN CLONED 3.13 PDSP; [29] 16.85 average sigma 3H-3-PPP,(+) RAT BRAIN >100,000 PDSP; [31] NEW PDSP BINDING ASSAYS For this study, the NIMH-PDSP ( http://pdsp.med.unc.edu/ ) has assayed sixteen phenylalkylamines, eight tryptamines and one ergoline (twenty-two psychedelics and three controls, Fig. 1 ) against a panel of fifty-one receptors, transporters, and ion channels. The methodology has been described previously by Glennon et al. [12] . Each compound is initially assayed at 10 µM against each receptor, transporter or ion channel (primary assay). Those that induce >50% inhibition (“hit”) are then assayed at 1, 10, 100, 1,000, and 10,000 nM to determine K i values (secondary assay). Each K i value (equilibrium dissociation constant, concentration at which 50% of the hot ligand is displaced by the test ligand) is calculated from at least three replicated assays. Details of how individual assays were conducted can be found at the NIMH-PDSP web site: http://pdsp.med.unc.edu/pdspw/binding.php . Table S2 shows raw K i data for the current study combined with data collected from the literature for the ten additional compounds; a total of thirty-five drugs and sixty-seven receptors, transporters and ion channels which were assayed. The table has been divided into three sections. The first section displays forty-two sites at which most compounds were assayed and at least one “hit” (K i <10,000 nm) was found: 5ht1a (5-HT 1A , serotonin-1A receptor), 5ht1b (5-HT 1B , serotonin-1B receptor), 5ht1d (5-HT 1D , serotonin-1D receptor), 5ht1e (5-HT 1E , serotonin-1E receptor), 5ht2a (5-HT 2A , serotonin-2A receptor), 5ht2b (5-HT 2B , serotonin-2B receptor), 5ht2c (5-HT 2C , serotonin-2C receptor), 5ht5a (5-HT 5A , serotonin-5A receptor), 5ht6 (5-HT 6 , serotonin-6 receptor), 5ht7 (5-HT 7 , serotonin-7 receptor), D1 (D 1 , dopamine-1 receptor), D2 (D 2 , dopamine-2 receptor), D3 (D 3 , dopamine-3 receptor), D4 (D 4 , dopamine-4 receptor), D5 (D 5 , dopamine-5 receptor), Alpha1A (α 1A , alpha-1A adrenergic receptor), Alpha1B (α 1B , alpha-1B adrenergic receptor), Alpha2A (α 2A , alpha-2A adrenergic receptor), Alpha2B (α 2B , alpha-2B adrenergic receptor), Alpha2C (α 2C , alpha-2C adrenergic receptor), Beta1 (β 1 , beta-1 adrenergic receptor), Beta2 (β 2 , beta-2 adrenergic receptor), SERT (serotonin transporter), DAT (dopamine transporter), NET (nor epinephrine transporter), Imidazoline1 (I 1 , imidazoline-1 receptor), Sigma1 (σ 1 , sigma-1 receptor), Sigma2 (σ 2 , sigma-2 receptor), DOR (delta opioid receptor), KOR (κ, kappa opioid receptor), MOR (μ, mu opioid receptor), M1 (M 1 , muscarinic-1 acetylcholine receptor), M2 (M 2 , muscarinic-2 acetylcholine receptor), M3 (M 3 , muscarinic-3 acetylcholine receptor), M4 (M 4 , muscarinic-4 acetylcholine receptor), M5 (M 5 , muscarinic-5 acetylcholine receptor), H1 (H 1 , histamine-1 receptor), H2 (H 2 , histamine-2 receptor), CB1 (CB 1 , cannabinoid-1 receptor), CB2 (CB 2 , cannabinoid-2 receptor), Ca+Channel (calcium+ ion channel), NMDA/MK801 (N-methyl D-aspartate glutamate receptor). The second section displays seven sites at which most compounds were assayed, but at which there were no hits: 5ht3 (serotonin-3 receptor), H3 (histamine-3 receptor), H4 (histamine-4 receptor), V1 (vasopressin-1 receptor), V2 (vasopressin-2 receptor), V3 (vasopressin-3 receptor), GabaA (GABA-A receptor). The third section displays the remaining eighteen sites, at which only a few compounds were assayed, and no hits were found: GabaB (GABA-B receptor), mGluR1a (mGluR1a metabotropic glutamate receptor), mGluR2 (mGluR2 metabotropic glutamate receptor), mGluR4 (mGluR4 metabotropic glutamate receptor), mGluR5 (mGluR5 metabotropic glutamate receptor), mGluR6 (mGluR6 metabotropic glutamate receptor), mGluR8 (mGluR8 metabotropic glutamate receptor), A2B2 (nicotinic a2/b2 acetylcholine receptor), A2B4 (nicotinic a2/b4 acetylcholine receptor), A3B2 (nicotinic a3/b2 acetylcholine receptor), A3B4 (nicotinic a3/b4 acetylcholine receptor), A4B2 (nicotinic a4/b2 acetylcholine receptor), A4B2** (nicotinic a4/b2** acetylcholine receptor), A4B4 (nicotinic a4/b4 acetylcholine receptor), BZP (a1) (GABA-BZP a1 receptor), EP3 (prostaglandin-3 receptor), MDR 1 (multidrug resistant p-Glycoprotein), PCP (PCP glutamate receptor). ACTIVITY ASSAYS For the twenty-five compounds of Fig. 1 , the NIMH-PDSP also performed activity assays at 5-HT 2A and 5-HT 2C . The E max values (maximal activity) are relative to 5-HT (serotonin), measuring Ca++ mobilization. Ca++ flux assays were performed using a FLIPRTETRA. The activity assays were conducted with cell lines which have very high receptor expression levels (e.g. plenty of ‘spare receptors’). Under such conditions partial agonists will have considerable agonist activity. The data represent the mean ± variance of computer-derived estimates from single experiments done in quadruplicate. Thus, the four observations are averaged and a single estimate with error is provided ( Table S3 ). SOURCES The following compounds ( Fig. 1 ) were used in the study: 2C-B, 4-Bromo-2,5-dimethoxyphenethylamine 2C-B-fly, 1-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b;4,5-b′]difuran-4-yl)2-aminoethane 2C-E, 4-Ethyl-2,5-dimethoxyphenethylamine 2C-T-2, 4-Ethylthio-2,5-dimethoxyphenethylamine ALEPH-2, (±)-4-Ethylthio-2,5-dimethoxyamphetamine 4C-T-2, 4-Ethylthio-2,5-dimethoxyphenylbutylamine MEM, (±)-2,5-Dimethoxy-4-ethoxyamphetamine TMA-2: (±)-2,4,5-Trimethoxamphetamine TMA: (±)-3,4,5-Trimethoxamphetamine mescaline: 3,4,5-Trimethoxyphenethylamine DOB: (±)-2,5-Dimethoxy-4-bromoamphetamine DOI: (±)-2,5-Dimethoxy-4-iodoamphetamine DOM: (±)-2,5-Dimethoxy-4-methylamphetamine DOET: (±)-2,5-Dimethoxy-4-ethylamphetamine MDA: (±)-3,4-Methylenedioxyamphetamine MDMA: (±)-3,4-Methylenedioxymethamphetamine DMT: N,N-Dimethyltryptamine 5-MeO-DMT: 5-Methoxy-N,N-dimethyltryptamine DPT: N,N-Dipropyltryptamine 5-MeO-MIPT: 5-Methoxy-N-methyl-N-isopropyltryptamine DIPT: N,N-Diisopropyltryptamine 5-MeO-DIPT: 5-Methoxy-N,N-diisopropyltryptamine 6-fluoro-DMT: 6-Fluoro-N,N-dimethyltryptamine psilocin: 4-Hydroxy-N,N-dimethyltryptamine lisuride 5-MeO-DMT, and DOI were purchased from Sigma. DOB, DOET, mescaline, TMA, MDA, MDMA, and psilocin were provided as gifts by the National Institute on Drug Abuse Drug Supply Program. 2C-B, 2C-B-fly, MEM, 4C-T-2, 5-MeO-MIPT, 6-fluoro-DMT, TMA-2, and lisuride were provided as gifts by Dave Nichols. DMT and DOM were provided as gifts by Richard Glennon. 2C-E, 2C-T-2, Aleph-2, DIPT, 5-MeO-DIPT, and DPT were provided as gifts by Alexander Shulgin. - 2C-B, 4-Bromo-2,5-dimethoxyphenethylamine - 2C-B-fly, 1-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b;4,5-b′]difuran-4-yl)2-aminoethane - 2C-E, 4-Ethyl-2,5-dimethoxyphenethylamine - 2C-T-2, 4-Ethylthio-2,5-dimethoxyphenethylamine - ALEPH-2, (±)-4-Ethylthio-2,5-dimethoxyamphetamine - 4C-T-2, 4-Ethylthio-2,5-dimethoxyphenylbutylamine - MEM, (±)-2,5-Dimethoxy-4-ethoxyamphetamine - TMA-2: (±)-2,4,5-Trimethoxamphetamine - TMA: (±)-3,4,5-Trimethoxamphetamine - mescaline: 3,4,5-Trimethoxyphenethylamine - DOB: (±)-2,5-Dimethoxy-4-bromoamphetamine - DOI: (±)-2,5-Dimethoxy-4-iodoamphetamine - DOM: (±)-2,5-Dimethoxy-4-methylamphetamine - DOET: (±)-2,5-Dimethoxy-4-ethylamphetamine - MDA: (±)-3,4-Methylenedioxyamphetamine - MDMA: (±)-3,4-Methylenedioxymethamphetamine - DMT: N,N-Dimethyltryptamine - 5-MeO-DMT: 5-Methoxy-N,N-dimethyltryptamine - DPT: N,N-Dipropyltryptamine - 5-MeO-MIPT: 5-Methoxy-N-methyl-N-isopropyltryptamine - DIPT: N,N-Diisopropyltryptamine - 5-MeO-DIPT: 5-Methoxy-N,N-diisopropyltryptamine - 6-fluoro-DMT: 6-Fluoro-N,N-dimethyltryptamine - psilocin: 4-Hydroxy-N,N-dimethyltryptamine - lisuride NORMALIZATION The raw K i values are distributed over several orders of magnitude, thus a log transformation is a good first step in the analysis. In addition, higher affinities produce lower K i values, thus it is valuable to calculate: pK i  = −log 10 (K i ). Higher affinities have higher pK i values, and each unit of pK i value corresponds to one order of magnitude of K i value. Table S4 presents the raw data transformed into pK i values. Generally, the highest K i value generated by NIMH-PDSP is 10,000, which produces a pK i value of −4 (although a value of 10,450 was reported for 5-MeO-TMT). For non-PDSP data gathered from the literature, some K i values greater than 10,000 are reported (i.e. 12,500, 14,142, 22,486, 39,409 and 70,000 for ibogaine). When the primary assay did not produce >50% inhibition, the K i value is treated as >10,000. When the primary assay hit, but the secondary assay was not performed, the K i value is also treated as >10,000. If a secondary assay produced a K i value significantly greater than 10,000, it is usually also reported as >10,000. The lowest K i value in the data set of this study is 0.3 (lisuride at 5-HT 1A ) and the highest value is 70,000 (ibogaine at D 3 ), thus collectively, the data in this study cover nearly six orders of magnitude of K i values. However, ignoring values reported as >10,000, the K i values for a single drug in this study never exceed four orders of magnitude in range. The goal of the normalization used in this study is to factor out potency, in order to allow easy comparison of the multi-receptor affinity profiles of different drugs. The normalization will adjust the highest pK i value for each drug to a value of 4, and set all K i values reported as >10,000 to a value of zero. K i values actually measured as greater than 10,000 are not set to zero (i.e. 5-MeO-TMT and ibogaine). We will call this normalized value npK i . Let the maximum pK i value for each drug be called pK iMax . For each individual drug: If K i treated as >10,000, then npK i  = 0 npK i  = 4+pK i −pK iMax With this normalization: higher affinities have higher values affinities too low to be measured will be reported as zero for each drug, the highest affinity will be set to a value of 4 each unit of npK i value represents one order of magnitude of K i value potency is factored out so that drugs of different potencies can be directly compared This normalization effectively factors out the absolute potency of each drug, and allows us to focus on the relative affinities of each drug at each receptor. - If K i treated as >10,000, then npK i  = 0 - npK i  = 4+pK i −pK iMax - higher affinities have higher values - affinities too low to be measured will be reported as zero - for each drug, the highest affinity will be set to a value of 4 - each unit of npK i value represents one order of magnitude of K i value - potency is factored out so that drugs of different potencies can be directly compared PERCEPTIBILITY It will also be seen that many psychedelic drugs interact with a large number of receptors. Fig. 3 shows the ranked distributions of npK i values for DOB and DOI, and the same data is listed below in numerical form (0.00 means K i >10,000, ND means the data is not available): The vertical axis is normalized pK i (npK i ). Horizontal axis is a list of forty-two receptors, arranged in order of decreasing affinity for each individual drug. Colors correspond to classes of receptors, and are the same as used in Fig. S1 . The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity. As a rule of thumb, this is presumed to be the limit of perceptible receptor interaction. Receptors to the right of the black bar should be imperceptible, while receptors to the left of the black bar should be perceptible, increasingly so the further left they are. DOB: 4.00 5ht2b, 3.23 5ht2a, 2.97 5ht2c, 2.11 Beta2, 1.89 5ht7, 1.82 Alpha2C, 1.79 5ht1d, 1.68 D3, 1.62 5ht1b, 1.53 M3, 1.44 5ht1e, 1.41 Alpha2B, 1.39 Imidazoline1, 1.25 Sigma1, 1.21 Beta1, 1.18 5ht1a, 0.96 Alpha2A, 0.87 5ht5a, 0.85 5ht6, 0.66 SERT, 0.63 H1; 0.00: D5, D2, D4, NET, D1, Alpha1B, Sigma2, DOR, KOR, MOR, M1, M2, DAT, M4, M5, Alpha1A, H2, CB2, CB1, Ca+Channel, NMDA DOI: 4.00 5ht2c, 3.79 Alpha2A, 3.52 Beta2, 3.44 5ht2a, 3.13 Alpha2B, 3.13 5ht2b, 3.00 5ht1d, 2.90 M4, 2.89 Beta1, 2.88 Alpha2C, 2.83 SERT, 2.66 5ht1e, 2.51 M3, 2.42 H1, 2.36 M2, 2.34 5ht6, 2.32 M5, 2.31 5ht1a, 2.23 M1, 1.90 5ht7, 1.73 Sigma1, 1.70 Sigma2, 1.67 D1; 0.00: 5ht1b, DAT, Imidazoline1, NET, 5ht5a, DOR, KOR, MOR, Alpha1B, D2, D3, D4, D5, Alpha1A, H2, CB2, CB1, NMDA; ND: Ca+Channel For potent compounds like DOB and DOI, it is possible to measure K i values over nearly a full four orders of magnitude range of affinity. However, not all of these affinities are able to produce perceptible mental effects. As a rule of thumb, 100-fold affinity is considered truly selective. Thus, receptors with npK i values below about 2.0 should not have perceptible mental effects. In Fig. 3 , a black vertical bar represent a 100-fold drop in affinity relative to the receptor with the highest affinity, and divides those npK i values greater than 2.0 (on the left) from those 2.0 or less (on the right). This is presumed to be the limit of perceptible receptor interaction. Receptors to the right of the black bar should be imperceptible, while receptors to the left of the black bar should be perceptible, increasingly so the further left they are. In spite of the long tail of affinities, DOB is effectively selective for the three 5-HT 2 (serotonin-2) receptors (Beta2 falls at the approximate limit of perceptibility), while DOI by contrast has nineteen receptors in the presumed perceptible range, although they should not all be equally perceptible. BREADTH An index of the breadth (or inverse of selectivity), B, of the binding profiles of the individual drugs or receptors can be constructed by summing the forty-two npK i values for each drug, or the thirty-five npK i values for each receptor. If a drug were absolutely selective, binding at only one receptor (e.g. salvinorin A), it would have the minimal B value of 4, regardless of the absolute affinity of the drug for its one receptor. If a drug bound with equal affinity to all forty-two receptors, it would have the maximum B value of 4×42 = 168, regardless of its absolute receptor affinities. It is not clear that a simple sum of npK i values is the best index of breadth. In this method, four receptors with K i values of 1,000 collectively carry the same weight as one receptor with a K i value of 1. This may not be a realistic equivalence. Thus we will include three measures of breadth: B sq and B exp give greater weight to higher affinity (lower K i ) values. Regression analysis of receptor affinity vs. potency in humans suggests that B sq is the most meaningful breadth statistic. Table S5 and Table S6 present the raw K i data converted into npK i values, for both the individual receptors, and groups of receptors summed using the B sq statistic. PROPORTIONAL BREADTH In addition to looking at the breadth of interaction of individual drugs with multiple receptors, it may be of value to look at an individual drug's interaction with one receptor or group of receptors, as a proportion of the drug's total interaction with all receptors. In order to compute the proportion for and individual receptor or a group of receptors, we divide the sum of squares of npK i values for the group of receptors, by the sum of squares of npK i values for all receptors: For example, to compute this proportion for “5-HT” receptors, we divide the squares of the values in the “5-HT” column of Table S5 (for LSD, 11.13 2  = 123.9), by the squares of the values in the center column (“B sq ”) of Table 3 (for LSD, 13.12 2  = 172.1); 123.9/172.1 = 0.719 for LSD. We will call this proportion B p . The proportional breadth data is displayed in Table S7 and Table S8 . The thirty-five drugs are arranged in order of decreasing breadth and increasing selectivity, based on the breadth indices B, B sq , and B exp . Although the three indices provide different orderings, the orderings are quite similar at the two extremes of the table (greatest and least breadth) where most of the attention is likely to be focused. The drugs with the broadest receptor interactions (least selective) are found at the tops of the columns, and the drugs with the narrowest receptor interactions (most selective) are found at the bottoms of the columns. TABLE: Thirty-five drugs arranged in order of decreasing breadth, increasing selectivity. B Drug B sq Drug B exp Drug 67.5 6-F-DMT 14.19 6-F-DMT 6.22 6-F-DMT 63.5 DPT 13.34 DMT 6.16 DMT 61.6 DOI 13.30 DPT 6.12 LSD 56.4 LSD 13.21 DOI 6.02 DPT 54.3 DMT 13.12 LSD 6.02 DOI 50.5 lisuride 11.88 lisuride 5.93 TMA 45.3 2C-E 11.61 2C-E 5.85 lisuride 45.2 cis-2a 11.55 TMA 5.81 2C-E 45.2 5-MeO-MIPT 11.37 2C-B 5.77 2C-B 43.9 2C-B 11.29 cis-2a 5.75 cis-2a 42.1 psilocin 11.00 5-MeO-MIPT 5.70 5-MeO-MIPT 40.5 2C-T-2 10.71 psilocin 5.60 psilocin 38.1 TMA 10.21 DIPT 5.52 DIPT 37.6 RR-2b 9.85 5-MeO-DIPT 5.49 5-MeO-DIPT 34.9 DIPT 9.80 RR-2b 5.44 4C-T-2 34.7 5-MeO-DMT 9.65 2C-T-2 5.44 RR-2b 34.5 DOB 9.64 4C-T-2 5.44 MDMA 33.4 SS-2c 9.50 MDMA 5.41 DOET 33.3 DOET 9.35 ibogaine 5.38 mescaline 32.5 2C-B-fly 9.32 DOET 5.36 2C-T-2 32.1 5-MeO-DIPT 9.00 5-MeO-DMT 5.36 5-MeO-DMT 31.2 ibogaine 8.85 SS-2c 5.35 ibogaine 31.1 4C-T-2 8.67 2C-B-fly 5.29 2C-B-fly 28.2 MDMA 8.67 mescaline 5.24 5-MeO-TMT 28.1 DOM 8.44 DOB 5.22 SS-2c 27.0 Aleph-2 8.41 5-MeO-TMT 5.16 DOB 22.9 5-MeO-TMT 8.29 DOM 5.10 DOM 21.1 mescaline 7.89 MDA 5.07 MDA 20.4 MDA 7.30 Aleph-2 4.94 Aleph-2 18.4 EMDT 7.22 EMDT 4.86 EMDT 13.0 TMA-2 6.60 TMA-2 4.78 TMA-2 10.3 MEM 5.50 THC 4.59 THC 7.8 THC 5.40 MEM 4.37 MEM 6.9 morphine 4.63 morphine 4.19 morphine 4.0 salvinorin A 4.00 salvinorin A 4.00 salvinorin A TRUNCATED RECEPTOR PROFILES The NIMH-PDSP generally does not measure K i values greater than 10,000 nm, because at those concentrations, there is a great deal of non-specific binding which invalidates the measurement of receptor affinity. This creates a problem for drugs whose best-hit has a K i value of greater that 100 nm (TMA, mescaline, TMA-2, DIPT, MDMA, 5-MeO-DIPT, ibogaine). For these drugs, the range of K i values that can be measured by the NIMH-PDSP is less than the 100-fold presumed perceptible range, and therefore, the lowest measurable npK i value is greater than the presumed limit of perceptibility at 2.00. Table 4 shows for each drug, the lowest K i value measured (K i Min) which is the best-hit, the best-hit receptor (K i MinR), the theoretically lowest measurable npK i value (npK i Lim), the lowest actually measured npK i value (npK i Min), and the receptor where the lowest npK i value was actually measured (npK i MinR). Drugs that have both a K i Min value of greater that 100 nm and an npK i Min value greater than 2.00 have truncated receptor affinity profiles. Table 4 shows for each drug, the lowest K i value measured (K i Min) which is the best-hit, the best-hit receptor (K i MinR), the theoretically lowest measurable npK i value (npK i Lim), the lowest actually measured npK i value (npK i Min), and the receptor where the lowest npK i value was actually measured (npK i MinR). Drugs that have both a K i Min value of greater that 100 nm and an npK i Min value greater than 2.00, have truncated receptor affinity profiles. Seven drugs have best-hit K i values of greater that 100 nm: TMA, mescaline, TMA-2, DIPT, MDMA, 5-MeO-DIPT, ibogaine. For these seven drugs, the perceptible receptor profile is truncated due to the methodological limitations of the NIMH-PDSP, to the extent to which the npK i Min value is greater than 2.00. Note that for ibogaine, whose best hit is 206 nm, the npK i Min value is 1.47, indicating that the receptor profile is not fully truncated, because several K i values above 10,000 nm were gathered from the literature (however, ibogaine has not received a full receptorome screening, and thus its receptor profile must be considered incomplete for other reasons). Six drugs have both a K i Min value of greater that 100 nm and an npK i Min value greater than 2.00. For 5-MeO-DIPT, the npK i Min value (2.15) is close to the presumed perceptibility limit, thus we can consider its receptor profile to be complete. For TMA-2, DIPT, and MDMA, the npK i Min values (2.58, 2.51, 2.43 respectively) fall in the weak region of the presumed perceptibility range. Although these three receptor profiles are truncated, the missing data may be of little consequence. For TMA and mescaline, the npK i Min values (2.98. 2.92 respectively) fall in the moderate region of the presumed perceptibility range. We must consider these two truncated receptor profiles to be truly incomplete, with potential consequences for our interpretations of the properties of these two drugs. The receptor profiles of some other drugs are incomplete due to holes in the NIMH-PDPS data set. Morphine and THC have not been broadly assayed, and must also be considered to be incomplete. TABLE: Truncated receptor profiles for thirty-five drugs. Drug KiMin KiMinR npKiLim npKiMin npKiMinR mescaline 745.3 Alpha2C 2.87 2.92 Alpha2A TMA 476.6 5ht2b 2.68 2.98 Alpha2C MDMA 219.7 Imidazoline1 2.34 2.43 M4 ibogaine 206 Sigma2 2.31 1.47 D3 TMA-2 154.4 5ht2b 2.19 2.58 5ht2c 5-MeO-DIPT 132.4 5ht1a 2.12 2.15 Sigma1 DIPT 120.5 5ht1a 2.08 2.51 5ht1d MDA 91 5ht2b 1.96 2.15 5ht2c DMT 87.5 5ht7 1.94 2.23 Sigma1 MEM 64.5 5ht2b 1.81 1.95 5ht7 5-MeO-TMT 60 5ht6 1.78 1.76 5ht5a 4C-T-2 58.1 5ht2b 1.76 1.77 5ht1e DOI 45.8 5ht2c 1.66 1.67 D1 DPT 31.8 5ht1a 1.50 1.54 D2 6-F-DMT 25.6 5ht6 1.41 1.56 Sigma2 2C-E 25.1 5ht2b 1.40 1.88 D2 EMDT 16 5ht6 1.20 1.54 5ht5a DOET 14.4 5ht1a 1.16 1.17 Sigma1 2C-B 13.5 5ht2b 1.13 1.28 D3 5-MeO-MIPT 12.3 5ht1a 1.09 1.28 SERT DOM 11.7 5ht2b 1.07 1.16 5ht6 THC 10.19 CB1 1.01 3.78 CB2 2C-T-2 6 5ht2b 0.78 0.81 Beta1 psilocin 4.7 5ht2b 0.67 1.03 Alpha2C salvinorin A 4.3 KOR 0.63 4 KOR LSD 3.9 5ht1b 0.59 0.65 Alpha1B DOB 3.9 5ht2b 0.59 0.63 H1 cis-2a 2.3 5ht1a 0.36 0.7 Beta2 RR-2b 2 5ht1b 0.30 0.59 Alpha1A 5-MeO-DMT 1.9 5ht1a 0.28 0.69 5ht2b Aleph-2 1.6 5ht2b 0.20 0.3 M5 2C-B-fly 0.9 5ht2b −0.05 0.12 D2 morphine 0.81 MOR −0.09 0.72 DOR SS-2c 0.4 5ht1a −0.40 0.2 H1 lisuride 0.3 5ht1a −0.52 1.08 Alpha1B RESULTS Fig. S1 shows the simplest view of the normalized affinity data. The drugs in Fig. S1 are ordered to correspond roughly to similarity of structure and receptor affinity profiles. Colors correspond to classes of receptors. It can be seen at a glance that most, but not all of the drugs interact strongly with the serotonin receptors (beige), certain drugs interact strongly with the dopamine receptors (red), others with the adrenergic receptors (green), yet others with the histamine receptors (yellow), etc. BREADTH In Table 3 , the thirty-five drugs are arranged in order of decreasing breadth and increasing selectivity, based on the three breadth indices B, B sq , and B exp . Although the three indices provide different orderings, the orderings are quite similar at the two extremes of the table (greatest and least breadth) where most of the attention is likely to be focused. The drugs with the broadest receptor interactions (least selective) are found at the tops of the columns, and the drugs with the narrowest receptor interactions (most selective) are found at the bottoms of the columns. Regression analysis suggests that B sq is the best statistic for combining receptors, therefore the B sq statistic will be used in most of the breadth analyses to follow. The B, B sq and B exp data of Table 3 is presented graphically in Fig. 4 . The thirty-five drugs are arranged in order of decreasing breadth and increasing selectivity, based on the breadth indices B, B sq , and B exp . Although the three indices provide different orderings, the orderings are quite similar at the two extremes of the table (greatest and least breadth) where most of the attention is likely to be focused. The drugs with the broadest receptor interactions (least selective) are found at the left of the figure, and the drugs with the narrowest receptor interactions (most selective) are found at the right of the figure. PROFILES OF DRUGS The relative breadth or selectivity of the thirty-five drugs is nicely visualized in Fig. S2 , in which for each drug, the bars representing forty-two receptors are arranged in order of decreasing size. The drugs are arranged in order of decreasing breadth, based on the B sq values of Table 3 and Fig. 4 . Drugs at the top of the figure have the broadest receptor interactions (least selective), while drugs at the bottom of the figure have the narrowest receptor interactions (most selective). Colors correspond to classes of receptors, and are the same as used in Fig. S1 . Scanning Fig. S2 from top to bottom shows the variation in breadth of receptor interactions between drugs. It can also be seen that some distributions are relatively convex (e.g. DMT & LSD), while others are relatively concave (e.g. DOB & 5-MeO-DMT). Convexity tends to increase breadth, while concavity tends to decrease breadth. It is also useful to present the npK i data of Fig. S2 in numerical format. In the listing below, the npK i values for each drug are arranged in decreasing order. A value of 0.00 means that the K i value was measured as >10,000 nm. “ND” indicates that the data is not available. The 5-HT 2A and 5-HT 2C receptors are also highlighted in bold font for easier location. npK i values below about 2.0 should be imperceptible, while values above about 2.0 should be perceptible, and the higher the npK i value, the more perceptible a receptor should be. 6-F-DMT: 4.00 5ht6, 3.93 5ht2b, 3.80 5ht7, 3.74 H1, 3.66 5ht1d, 3.25 SERT, 3.24 Alpha2C, 3.17 Alpha1A, 3.07 5ht1b, 2.99 Alpha2B, 2.81 5ht1a, 2.74 5ht1e, 2.67 D1, 2.62 D2, 2.58 5ht2c , 2.47 5ht2a , 2.47 D3, 2.45 Imidazoline1, 2.44 H2, 2.43 5ht5a, 2.25 D4, 1.61 D5, 1.57 Sigma1, 1.56 Sigma2; 0.00: DAT, Beta1, NET, Alpha2A, CB2, CB1, Ca+Channel, Beta2, M2, M3, M4, M5, M1, Alpha1B, NMDA; ND: DOR, MOR, KOR DMT: 4.00 5ht7, 3.97 5ht1d, 3.91 5ht2b, 3.53 Alpha2B, 3.53 Alpha2C, 3.51 D1, 3.42 5ht2c , 3.28 5ht1e, 3.25 5ht6, 3.16 5ht5a, 3.13 Imidazoline1, 2.95 Alpha1B, 2.75 Alpha2A, 2.70 Alpha1A, 2.58 5ht2a , 2.37 SERT, 2.23 Sigma1; 0.00: 5ht1a, D4, D5, Beta1, D2, D3, DAT, NET, 5ht1b, Beta2, Sigma2, CB2, KOR, Ca+Channel, M1, M2, M3, M4, M5, H2, CB1; ND: H1, DOR, MOR, NMDA DPT: 4.00 5ht1a, 3.88 5ht2b, 3.41 H1, 3.31 SERT, 3.05 5ht7, 2.97 Imidazoline1, 2.97 Alpha2B, 2.90 Sigma1, 2.86 Alpha1B, 2.84 Alpha2A, 2.79 Alpha2C, 2.71 5ht1d, 2.57 5ht1b, 2.56 Alpha1A, 2.37 D3, 2.33 DAT, 2.31 5ht2c , 2.20 D4, 2.13 5ht1e, 2.09 5ht2a , 2.04 Sigma2, 1.86 5ht5a, 1.85 5ht6, 1.54 D2; 0.00: D1, D5, NET, Beta1, DOR, KOR, MOR, Beta2, M2, M3, M4, M5, M1, H2, CB2, CB1, Ca+Channel, NMDA DOI: 4.00 5ht2c , 3.79 Alpha2A, 3.52 Beta2, 3.44 5ht2a , 3.13 Alpha2B, 3.13 5ht2b, 3.00 5ht1d, 2.90 M4, 2.89 Beta1, 2.88 Alpha2C, 2.83 SERT, 2.66 5ht1e, 2.51 M3, 2.42 H1, 2.36 M2, 2.34 5ht6, 2.32 M5, 2.31 5ht1a, 2.23 M1, 1.90 5ht7, 1.73 Sigma1, 1.70 Sigma2, 1.67 D1; 0.00: 5ht1b, DAT, Imidazoline1, NET, 5ht5a, DOR, KOR, MOR, Alpha1B, D2, D3, D4, D5, Alpha1A, H2, CB2, CB1, NMDA; ND: Ca+Channel LSD: 4.00 5ht1b, 3.77 5ht7, 3.75 5ht6, 3.73 5ht1a, 3.70 5ht1d, 3.64 5ht5a, 3.54 5ht2a , 3.16 D3, 3.11 5ht2b, 3.11 5ht2c , 2.93 Alpha2A, 2.62 5ht1e, 2.55 D2, 2.39 D4, 2.34 D1, 2.05 D5, 1.54 Alpha1A, 1.40 H1, 1.39 Beta1, 1.05 Beta2, 0.65 Alpha1B; 0.00: KOR, DOR, DAT, SERT, MOR, NET; ND: Sigma2, Alpha2B, Alpha2C, Imidazoline1, M1, M2, M3, M4, M5, Sigma1, H2, CB2, CB1, Ca+Channel, NMDA lisuride: 4.00 5ht1a, 3.88 Alpha2C, 3.78 Alpha2B, 3.22 Alpha2A, 3.01 5ht2b, 2.99 5ht5a, 2.90 D4, 2.74 5ht2a , 2.65 D2, 2.64 5ht7, 2.61 5ht6, 2.56 Beta1, 2.27 5ht1b, 2.09 Alpha1A, 1.93 Beta2, 1.83 5ht1e, 1.59 D5, 1.42 H2, 1.34 D3, 1.08 Alpha1B; 0.00: 5ht1d, 5ht2c , D1, DAT, NET, Imidazoline1, M1, SERT, CB2, KOR, MOR, M3, M2, M5, M4, CB1, Ca+Channel; ND: Sigma1, H1, Sigma2, DOR, NMDA 2C-E: 4.00 5ht2b, 3.76 5ht2a , 3.54 5ht1d, 3.44 Alpha2C, 3.38 5ht2c , 3.00 5ht1b, 2.91 Alpha2B, 2.91 5ht1a, 2.77 5ht7, 2.71 Alpha2A, 2.60 5ht1e, 2.27 D3, 2.16 M5, 1.99 M3, 1.93 5ht6, 1.88 D2; 0.00: D1, Alpha1A, Alpha1B, 5ht5a, Beta1, M1, SERT, D4, NET, Imidazoline1, H1, Sigma2, DOR, KOR, MOR, NMDA, M2, DAT, M4, D5, CB2, H2, Ca+Channel, CB1; ND: Sigma1, Beta2 TMA: 4.00 5ht2b, 3.95 Sigma2, 3.95 Sigma1, 3.80 5ht7, 3.45 5ht1a, 3.36 Alpha2A, 3.22 5ht1b, 3.20 5ht1d, 3.15 5ht1e, 3.02 5ht2c , 2.98 Alpha2C; 0.00: 5ht2a , 5ht6, D4, D1, Alpha1A, D2, D3, Alpha2B, D5, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, Alpha1B, 5ht5a, DOR, KOR, MOR, NMDA, M2, CB2, CB1, M5, H1, H2; ND: M3, M4, Ca+Channel, M1 2C-B: 4.00 5ht2b, 3.71 5ht1d, 3.69 5ht2a , 3.18 5ht2c , 3.12 Alpha2C, 3.11 5ht1b, 3.05 5ht1e, 2.81 5ht7, 2.75 5ht1a, 2.64 Alpha2A, 2.63 5ht6, 2.31 Alpha2B, 2.22 M3, 1.80 Imidazoline1, 1.60 D2, 1.28 D3; 0.00: D1, 5ht5a, Alpha1B, D5, NMDA, M1, SERT, D4, NET, Alpha1A, Sigma1, Sigma2, DOR, KOR, MOR, H1, M2, DAT, M4, M5, CB2, H2, CB1; ND: Beta2, Ca+Channel, Beta1 cis-2a: 4.00 5ht1a, 3.79 5ht1b, 3.46 D3, 3.30 5ht7, 3.25 5ht6, 3.15 5ht5a, 2.89 5ht2a , 2.72 5ht2b, 2.67 D2, 2.49 D4, 2.34 5ht2c , 2.07 5ht1e, 2.00 D1, 1.76 Beta1, 1.66 H1, 1.64 Alpha1A, 1.36 D5, 0.70 Beta2; 0.00: DOR, SERT, MOR, KOR, NET, DAT, Alpha1B; ND: 5ht1d, Alpha2A, Sigma2, Alpha2B, Alpha2C, Imidazoline1, M1, M2, M3, M4, M5, Sigma1, H2, CB2, CB1, Ca+Channel, NMDA 5-MeO-MIPT: 4.00 5ht1a, 3.79 5ht7, 3.74 5ht1d, 3.32 5ht2b, 2.98 5ht6, 2.85 Alpha2A, 2.61 5ht1b, 2.44 5ht2a , 2.29 Alpha2C, 2.15 Imidazoline1, 2.13 Sigma2, 2.11 5ht5a, 1.86 Alpha2B, 1.75 5ht2c , 1.70 D3, 1.55 5ht1e, 1.41 H1, 1.29 D4, 1.28 SERT; 0.00: D2, Alpha1B, D5, D1, Beta2, NET, DAT, Sigma1, Beta1, DOR, KOR, MOR, M1, M2, M3, M4, M5, Alpha1A, H2, CB2, NMDA, Ca+Channel; ND: CB1 Psilocin: 4.00 5ht2b, 3.40 5ht1d, 3.37 D1, 3.03 5ht1e, 2.88 5ht1a, 2.83 5ht5a, 2.82 5ht7, 2.82 5ht6, 2.67 D3, 2.52 5ht2c , 2.19 5ht1b, 2.14 5ht2a , 1.77 Imidazoline1, 1.74 SERT, 1.57 Alpha2B, 1.36 Alpha2A, 1.03 Alpha2C; 0.00: D2, Alpha1B, D5, D4, Beta2, Beta1, DAT, NET, Alpha1A, Sigma1, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, Ca+Channel, H1, H2, CB2, CB1; ND: M5, NMDA DIPT: 4.00 5ht1a, 3.53 Imidazoline1, 3.48 5ht2b, 2.98 SERT, 2.83 Sigma1, 2.68 Alpha2C, 2.65 Sigma2, 2.62 Alpha2B, 2.56 D3, 2.55 5ht7, 2.53 H1, 2.51 5ht1d; 0.00: 5ht2a , D4, 5ht5a, D1, D2, Alpha2A, 5ht6, D5, Beta1, Beta2, 5ht2c , DAT, NET, 5ht1b, Alpha1B, 5ht1e, DOR, KOR, MOR, M1, M2, M3, M4, M5, Alpha1A, H2, CB2, CB1, Ca+Channel, NMDA 5-MeO-DIPT: 4.00 5ht1a, 3.91 5ht2b, 3.24 Imidazoline1, 3.03 5ht7, 2.89 5ht1d, 2.72 SERT, 2.66 Alpha2C, 2.64 Sigma2, 2.41 5ht1b, 2.40 Alpha2B, 2.15 Sigma1; 0.00: 5ht5a, 5ht2a , D4, D3, D1, D2, Alpha2A, 5ht6, D5, Beta1, Beta2, 5ht2c , DAT, NET, Alpha1A, Alpha1B, 5ht1e, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel, NMDA RR-2b: 4.00 5ht1b, 3.59 5ht1a, 3.20 5ht5a, 3.05 5ht1d, 2.81 5ht7, 2.52 5ht6, 2.40 D3, 2.16 5ht1e, 2.08 D4, 1.88 D2, 1.81 5ht2b, 1.77 D1, 1.63 5ht2c , 1.53 D5, 1.46 5ht2a , 1.14 H1, 0.59 Alpha1A; 0.00: SERT, DOR, KOR, MOR, Alpha1B, NET, DAT; ND: Alpha2A, Imidazoline1, Beta2, Sigma2, Alpha2B, Alpha2C, Beta1, M1, M2, M3, M4, M5, Sigma1, H2, CB2, CB1, Ca+Channel, NMDA 2C-T-2: 4.00 5ht2b, 3.18 5ht2a , 3.05 5ht2c , 2.84 5ht1d, 2.56 Alpha2C, 2.20 5ht1a, 2.16 5ht1e, 1.94 M3, 1.92 Alpha2A, 1.84 5ht1b, 1.79 Alpha2B, 1.79 5ht7, 1.70 Beta2, 1.64 5ht6, 1.60 M5, 1.51 D3, 1.46 Imidazoline1, 1.33 D2, 1.19 Sigma1, 0.81 Beta1; 0.00: D1, 5ht5a, SERT, D4, NET, Alpha1A, Alpha1B, Sigma2, DOR, KOR, MOR, M1, M2, DAT, M4, D5, H1, H2, CB2, CB1, Ca+Channel, NMDA 4C-T-2: 4.00 5ht2b, 3.67 Beta2, 3.33 5ht2a , 3.09 5ht2c , 3.05 Sigma1, 2.79 Imidazoline1, 2.66 D3, 2.56 5ht5a, 2.18 5ht7, 2.04 5ht1a, 1.77 5ht1e; 0.00: 5ht6, D1, D4, D5, Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, D2, SERT, DAT, NET, 5ht1b, 5ht1d, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel, NMDA MDMA: 4.00 Imidazoline1, 3.64 5ht2b, 3.26 Ca+Channel, 3.21 Alpha2C, 3.09 Alpha2B, 3.07 M3, 2.94 Alpha2A, 2.54 M5, 2.43 M4; 0.00: 5ht2c , 5ht1d, D2, 5ht1e, 5ht1a, 5ht2a , Alpha1A, Alpha1B, 5ht5a, 5ht6, 5ht7, D1, Beta2, SERT, DAT, NET, 5ht1b, H1, H2, D3, KOR, Beta1, M1, M2, D5, D4, CB1, NMDA, MOR; ND: DOR, Sigma2, CB2, Sigma1 Ibogaine: 4.00 Sigma2, 3.57 SERT, 3.02 DAT, 3.01 NMDA, 2.88 KOR, 2.67 MOR, 2.55 Sigma1, 2.22 M3, 2.16 5ht2a , 1.96 M1, 1.72 M2, 1.47 D3; 0.00: DOR, 5ht1b, 5ht1d, 5ht1a, H1, 5ht2c , D2, D1, Beta1; ND: Alpha2C, D5, D4, Alpha2B, Imidazoline1, NET, Alpha2A, 5ht5a, 5ht6, 5ht7, Alpha1B, 5ht1e, 5ht2b, M4, M5, Alpha1A, H2, CB2, CB1, Ca+Channel, Beta2 DOET: 4.00 5ht1a, 3.72 5ht2a , 3.70 5ht2b, 3.13 5ht2c , 2.40 Alpha2B, 2.07 5ht7, 2.05 Alpha2A, 2.00 Alpha2C, 1.82 Beta2, 1.71 5ht1b, 1.61 5ht1e, 1.40 Beta1, 1.34 5ht1d, 1.18 Sigma2, 1.17 Sigma1; 0.00: D4, Alpha1A, D3, 5ht6, D5, D1, D2, SERT, DAT, NET, Imidazoline1, Alpha1B, 5ht5a, DOR, KOR, MOR, NMDA, M2, CB2, CB1, M5, H1, H2; ND: M3, M4, Ca+Channel, M1 5-MeO-DMT: 4.00 5ht1a, 3.69 5ht7, 3.48 5ht1d, 2.73 5ht6, 2.41 5ht1b, 2.38 D1, 1.84 5ht5a, 1.72 5ht1e, 1.58 D3, 1.57 Alpha2C, 1.55 5ht2c , 1.00 Alpha2A, 0.98 5ht2a , 0.97 SERT, 0.88 Imidazoline1, 0.86 Alpha2B, 0.82 NET, 0.78 D4, 0.73 D2, 0.69 5ht2b; 0.00: Alpha1B, Beta2, Beta1, DAT, D5, Alpha1A, Sigma1, Sigma2, CB2, KOR, Ca+Channel, M1, M2, M3, M4, M5, H2, CB1; ND: H1, DOR, MOR, NMDA SS-2c: 4.00 5ht1a, 3.22 5ht1b, 2.82 D3, 2.45 5ht7, 2.44 5ht6, 2.32 5ht2a , 2.17 5ht5a, 2.17 5ht2b, 2.03 5ht2c , 1.74 D2, 1.72 Beta1, 1.62 D4, 1.16 5ht1e, 1.14 D1, 1.00 D5, 0.67 Alpha1A, 0.57 Beta2, 0.20 H1; 0.00: DOR, SERT, MOR, KOR, NET, DAT, Alpha1B; ND: 5ht1d, Alpha2A, Sigma2, Alpha2B, Alpha2C, Imidazoline1, M1, M2, M3, M4, M5, Sigma1, H2, CB2, CB1, Ca+Channel, NMDA 2C-B-fly: 4.00 5ht2b, 3.81 5ht1d, 2.93 5ht2c , 2.89 5ht2a , 1.91 5ht1e, 1.79 5ht1a, 1.79 Alpha2A, 1.78 5ht6, 1.69 5ht1b, 1.59 Alpha2C, 1.42 M3, 1.24 M4, 1.17 5ht7, 1.16 Alpha2B, 1.15 M1, 1.01 M5, 0.65 M2, 0.26 D1, 0.19 H1, 0.12 D2; 0.00: Beta1, Alpha1B, 5ht5a, DAT, NET, Imidazoline1, Sigma1, Sigma2, DOR, KOR, MOR, Beta2, SERT, CB2, D4, D5, Alpha1A, H2, CB1; ND: D3, Ca+Channel, NMDA Mescaline: 4.00 Alpha2C, 3.97 5ht2b, 3.61 5ht1a, 3.44 Imidazoline1, 3.16 5ht1e, 2.92 Alpha2A; 0.00: 5ht2a , 5ht2c , 5ht6, 5ht1d, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, 5ht5a, Alpha2B, 5ht7, Beta1, Beta2, SERT, DAT, NET, 5ht1b, Sigma1, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel, NMDA DOB: 4.00 5ht2b, 3.23 5ht2a , 2.97 5ht2c , 2.11 Beta2, 1.89 5ht7, 1.82 Alpha2C, 1.79 5ht1d, 1.68 D3, 1.62 5ht1b, 1.53 M3, 1.44 5ht1e, 1.41 Alpha2B, 1.39 Imidazoline1, 1.25 Sigma1, 1.21 Beta1, 1.18 5ht1a, 0.96 Alpha2A, 0.87 5ht5a, 0.85 5ht6, 0.66 SERT, 0.63 H1; 0.00: D5, D2, D4, NET, D1, Alpha1B, Sigma2, DOR, KOR, MOR, M1, M2, DAT, M4, M5, Alpha1A, H2, CB2, CB1, Ca+Channel, NMDA 5-MeO-TMT: 4.00 5ht6, 3.62 5ht7, 3.48 5ht1a, 3.38 5ht1d, 2.52 5ht1e, 2.17 5ht2c , 1.97 NET, 1.76 5ht5a; 0.00: 5ht2a , DAT, D1, D2, D3, D4, D5, H1, H2, SERT, DOR, KOR, MOR; ND: Beta2, Alpha2A, 5ht2b, 5ht1b, Imidazoline1, Sigma1, Sigma2, Alpha2B, Alpha2C, Beta1, M1, M2, M3, M4, M5, Alpha1A, Alpha1B, CB2, CB1, Ca+Channel, NMDA DOM: 4.00 5ht2b, 3.38 Beta2, 2.75 5ht1d, 2.36 5ht2a , 2.30 Alpha2A, 2.13 Alpha2B, 2.10 Alpha2C, 1.87 5ht7, 1.56 Alpha1A, 1.52 5ht1e, 1.51 5ht1a, 1.47 5ht2c , 1.16 5ht6; 0.00: D3, 5ht1b, D1, Alpha1B, 5ht5a, D4, D5, Beta1, D2, SERT, DAT, NET, Imidazoline1, Sigma1, Sigma2, DOR, KOR, MOR, M1, M2, CB2, CB1, M5, H1, H2, NMDA; ND: M3, Ca+Channel, M4 MDA: 4.00 5ht2b, 3.60 Alpha2C, 3.12 Alpha2B, 2.74 Alpha2A, 2.41 5ht7, 2.38 5ht1a, 2.15 5ht2c ; 0.00: 5ht2a , 5ht1e, 5ht1d, D1, D2, D3, D4, 5ht1b, Alpha1A, Alpha1B, 5ht5a, 5ht6, D5, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, CB2, H2, M5, KOR, M2, CB1; ND: M1, M3, Sigma1, MOR, H1, Sigma2, DOR, M4, Ca+Channel, NMDA Aleph-2: 4.00 5ht2b, 2.79 Beta2, 2.50 5ht2c , 2.42 5ht2a , 1.83 Sigma1, 1.70 Imidazoline1, 1.41 D3, 1.08 5ht7, 1.08 SERT, 1.06 Alpha2C, 1.02 5ht1d, 0.98 5ht1a, 0.92 M3, 0.90 5ht1b, 0.74 Alpha2B, 0.72 5ht6, 0.71 5ht1e, 0.44 Alpha2A, 0.37 Beta1, 0.30 M5; 0.00: D1, D2, 5ht5a, D4, NET, Alpha1A, Alpha1B, Sigma2, DOR, KOR, MOR, M1, M2, DAT, M4, D5, H1, H2, CB2, CB1, Ca+Channel, NMDA EMDT: 4.00 5ht6, 2.97 5ht1a, 2.74 5ht1d, 2.73 5ht7, 2.49 5ht1e, 1.95 5ht2c , 1.54 5ht5a; 0.00: 5ht2a , DAT, D5, D1, D2, D3, D4, NET, H1, H2, SERT, DOR, KOR, MOR; ND: Beta2, Alpha2A, 5ht2b, 5ht1b, Imidazoline1, Sigma1, Sigma2, Alpha2B, Alpha2C, Beta1, M1, M2, M3, M4, M5, Alpha1A, Alpha1B, CB2, CB1, Ca+Channel, NMDA TMA-2: 4.00 5ht2b, 3.42 5ht2a , 3.04 H1, 2.58 5ht2c ; 0.00: 5ht1b, 5ht1a, 5ht1e, 5ht5a, 5ht6, 5ht7, D1, D2, D3, D4, D5, 5ht1d, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, SERT, DAT, NET, M5, Alpha1A, H2, M2; ND: KOR, DOR, M1, MOR, M3, M4, Imidazoline1, Sigma1, Sigma2, CB2, CB1, Ca+Channel, NMDA THC: 4.00 CB1, 3.78 CB2; ND: 5ht2a , 5ht2c , 5ht1b, 5ht1d, 5ht1e, 5ht2b, 5ht1a, 5ht7, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, 5ht5a, 5ht6, Alpha2C, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, Sigma1, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2, Alpha2A, Alpha2B, Ca+Channel, NMDA MEM: 4.00 5ht2b, 2.21 5ht2a , 2.10 Sigma1, 1.95 5ht7; 0.00: 5ht2c , 5ht1a, 5ht1e, 5ht5a, 5ht6, 5ht1b, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, 5ht1d, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel, NMDA Morphine: 4.00 MOR, 2.21 KOR, 0.72 DOR; ND: 5ht2c , 5ht2a , 5ht1d, 5ht1e, 5ht2b, 5ht1a, 5ht1b, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, Sigma1, Sigma2, 5ht5a, 5ht6, 5ht7, M1, M2, M3, M4, M5, H1, H2, CB2, CB1, Ca+Channel, NMDA Salvinorin A: 4.00 KOR; 0.00: 5ht2a , 5ht2b, 5ht2c , 5ht1b, 5ht1d, 5ht1e, 5ht5a, 5ht1a, 5ht7, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, SERT, DOR, 5ht6, Beta1, Beta2, M2, DAT, M4, M5, H1, M1, M3, MOR; ND: Alpha2A, Alpha2C, Sigma2, Alpha2B, NET, Imidazoline1, Sigma1, H2, CB2, CB1, Ca+Channel, NMDA GROUPS OF RELATED RECEPTORS In addition to looking at breadth at the full complement of forty-two receptors with which the drugs interact, we can use the B sq statistic to look at the participation of selected groups of receptors ( Table S5 ). 5-HT 6 and 5-HT 7 are grouped because they share a common G-protein, G s [13] . The same data is also presented in Table S6 , which also includes interactions with individual receptors. Tables S5 and S6 allow us to easily identify drugs with the greatest or least interaction with an individual receptor or any group of related receptors. For example, among drugs with measurable affinity at a 5-HT 2 receptor, 5-MeO-DMT has the weakest interaction with both the three 5-HT 2 receptors and the two paradigmatic 5-HT 2 receptors (5-HT 2A/C ). This can be seen in that 5-MeO-DMT has the lowest non-zero value in all four of the columns: “5-HT 2 ,” “5-HT 2 max,” “5-HT 2A , 5-HT 2C ,” and “5-HT 2A/C max.” Meanwhile, the drugs 2C-E and DOI rise to the top of the same four columns, indicating that they have the strongest interactions with the 5-HT 2 receptors (fourteen drugs tie for the top value in the 5-HT 2 max column because thirteen drugs have 5-HT 2B as their best hit and one has 5-HT 2C as its best hit). LSD has the strongest interaction collectively with the five dopamine receptors (D 1 , D 2 , D 3 , D 4 , D 5 ), the ten assayed 5-HT receptors, and the four assayed 5-HT 1 (serotonin-1) receptors. DMT has the strongest interaction with any single dopamine receptor (Dmax), and is the only drug to have its best hit at the 5-HT 7 receptor ( Table S6 ). Mescaline is the only drug to have its best hit at an adrenergic receptor (α 2C , Table S6 ). Ibogaine is the only drug to have its best hit at a sigma receptor. MDMA is the only drug to have its best hit at an imidazoline receptor ( Table S6 ). These observations likely provide clues to the qualitative diversity of these drugs. PROPORTIONAL BREADTH There is yet another way to look at the participation of the sub-sets of receptors. It may be relevant to consider the participation of a sub-set of receptors in proportion to the participation of all receptors ( Table S7 ). For this we use the proportional breadth statistic (B p ) described in the methods section. The same data is also displayed in Table S8 . The proportional breadth statistic, B p , is strongly influenced by the degree of overall breadth of the drug (B sq 2 ), as this determines the denominator in calculating the proportion. Therefore, we find MEM at the top of the 5-HT column because it is almost completely selective for a single receptor, 5-HT 2B . Similarly, TMA-2 is at the top of the 5-HT 2 columns because it is highly selective for the 5-HT 2 receptors, and EMDT is at the top of the “5-HT 6 , 5-HT 7 ” column because it is highly selective for the 5-HT 6 receptor. Due to their high degree of selectivity, MEM, TMA-2, and EMDT all have small denominators in calculating the B p statistic. More interesting cases involve less selective drugs. For example, DMT is a very promiscuous drug, yet it falls at the top of the “α 1A , α 1B ” column. MDA falls at the top of the “Adrenergic” and “α 2A , α 2B , α 2C ” columns. 5-MeO-DMT appears third from the top of the “5-HT 6 , 5-HT 7 ” column and second from the top of the “5-HT 7 ” column ( Table S8 ). Ibogaine appears at the top of the “σ 1 , σ 2 ” column. Although fairly selective, TMA-2's position at the top of the “H 1 , H 2 ” column represents an important aspect of its pharmacology, likewise for DOM's position at the top of the “β 1 , β 2 ” column. PROFILES OF RECEPTORS The B statistics can also be used to look at the relative role played by the various receptors in the pharmacology of the entire set of drugs of this study. In this case, for each receptor, we sum the npK i values at each receptor across each of the thirty-five drugs. In Table 5 we can see the rankings from the three B statistics. The data in Table 5 can also be represented graphically ( Fig. 5 ). The three B statistics provide a very consistent ranking for the top seven receptors. In descending order of importance: 5-HT 2B , 5-HT 1A , 5-HT 7 , 5-HT 1D , 5-HT 2A , 5-HT 2C , α 2C (with some play between the sixth and seventh positions). This set of top receptors would be a good place to look for receptors other than 5-HT 2A and 5-HT 2C , which play an important role in the actions of psychedelic drugs. The forty-two receptors are arranged in order of decreasing interaction with the full set of thirty-five drugs, based on the breadth statistics, B, B sq . and B exp . The receptors with the greatest interactions are found at the left of the figures, and the receptors with the least interactions are found at the right of the figures. The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity at each drug. As a rule of thumb, this is presumed to be the limit of perceptible receptor interaction. Drugs to the right of the black bar should have imperceptible interactions with the receptor, while drugs to the left of the black bar should have perceptible interactions with the receptor, increasingly so the further left they are. The forty-two receptors are arranged in order of decreasing interaction with the full set of thirty-five drugs, based on the breadth statistics B, B sq . and B exp . The receptors with the greatest interactions are found at the tops of the columns, and the receptors with the least interactions are found at the bottoms of the columns. Fig. S3 is a more detailed graphical view of data presented in Table 5 . The receptors are presented in order of decreasing breadth (B sq ). The figures for each individual receptor provide information on the relative importance of each receptor at each drug, similar to that in Table S5 and Table S6 . Receptors at the top of the figure have the broadest interactions with the thirty-five drugs, while receptors at the bottom of the figure have the narrowest interactions with the thirty-five drugs. The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity at each drug. As a rule of thumb, this is presumed to be the limit of perceptible receptor interaction. Drugs to the right of the black bar should have imperceptible interactions with the receptor, while drugs to the left of the black bar should have perceptible interactions with the receptor, increasingly so the further left they are. It is also useful to present the npK i data of Fig. S3 in numerical format. npK i values below about 2.0 should be imperceptible, while values above about 2.0 should be perceptible, and the higher the npK i value, the more perceptible a receptor should be at a particular drug. 5ht2b: 4.00 DOB, 4.00 MDA, 4.00 Aleph-2, 4.00 2C-B-fly, 4.00 2C-B, 4.00 TMA, 4.00 psilocin, 4.00 TMA-2, 4.00 2C-E, 4.00 2C-T-2, 4.00 4C-T-2, 4.00 MEM, 4.00 DOM, 3.97 mescaline, 3.93 6-F-DMT, 3.91 5-MeO-DIPT, 3.91 DMT, 3.88 DPT, 3.70 DOET, 3.64 MDMA, 3.48 DIPT, 3.32 5-MeO-MIPT, 3.13 DOI, 3.11 LSD, 3.01 lisuride, 2.72 cis-2a, 2.17 SS-2c, 1.81 RR-2b, 0.69 5-MeO-DMT; 0.00 salvinorin A; ND: 5-MeO-TMT, ibogaine, EMDT, morphine, THC 5ht1a: 4.00 5-MeO-MIPT, 4.00 lisuride, 4.00 DOET, 4.00 SS-2c, 4.00 5-MeO-DIPT, 4.00 DIPT, 4.00 5-MeO-DMT, 4.00 cis-2a, 4.00 DPT, 3.73 LSD, 3.61 mescaline, 3.59 RR-2b, 3.48 5-MeO-TMT, 3.45 TMA, 2.97 EMDT, 2.91 2C-E, 2.88 psilocin, 2.81 6-F-DMT, 2.75 2C-B, 2.38 MDA, 2.31 DOI, 2.20 2C-T-2, 2.04 4C-T-2, 1.79 2C-B-fly, 1.51 DOM, 1.18 DOB, 0.98 Aleph-2; 0.00: TMA-2, MEM, MDMA, DMT, ibogaine, salvinorin A; ND: morphine, THC 5ht7: 4.00 DMT, 3.80 6-F-DMT, 3.80 TMA, 3.79 5-MeO-MIPT, 3.77 LSD, 3.69 5-MeO-DMT, 3.62 5-MeO-TMT, 3.30 cis-2a, 3.05 DPT, 3.03 5-MeO-DIPT, 2.82 psilocin, 2.81 2C-B, 2.81 RR-2b, 2.77 2C-E, 2.73 EMDT, 2.64 lisuride, 2.55 DIPT, 2.45 SS-2c, 2.41 MDA, 2.18 4C-T-2, 2.07 DOET, 1.95 MEM, 1.90 DOI, 1.89 DOB, 1.87 DOM, 1.79 2C-T-2, 1.17 2C-B-fly, 1.08 Aleph-2; 0.00: TMA-2, MDMA, mescaline, salvinorin A; ND: ibogaine, morphine, THC 5ht1d: 3.97 DMT, 3.81 2C-B-fly, 3.74 5-MeO-MIPT, 3.71 2C-B, 3.70 LSD, 3.66 6-F-DMT, 3.54 2C-E, 3.48 5-MeO-DMT, 3.40 psilocin, 3.38 5-MeO-TMT, 3.20 TMA, 3.05 RR-2b, 3.00 DOI, 2.89 5-MeO-DIPT, 2.84 2C-T-2, 2.75 DOM, 2.74 EMDT, 2.71 DPT, 2.51 DIPT, 1.79 DOB, 1.34 DOET, 1.02 Aleph-2; 0.00: 4C-T-2, mescaline, TMA-2, MEM, lisuride, MDMA, salvinorin A, MDA, ibogaine; ND: cis-2a, SS-2c, morphine, THC 5ht2a: 3.76 2C-E, 3.72 DOET, 3.69 2C-B, 3.54 LSD, 3.44 DOI, 3.42 TMA-2, 3.33 4C-T-2, 3.23 DOB, 3.18 2C-T-2, 2.89 2C-B-fly, 2.89 cis-2a, 2.74 lisuride, 2.58 DMT, 2.47 6-F-DMT, 2.44 5-MeO-MIPT, 2.42 Aleph-2, 2.36 DOM, 2.32 SS-2c, 2.21 MEM, 2.16 ibogaine, 2.14 psilocin, 2.09 DPT, 1.46 RR-2b, 0.98 5-MeO-DMT; 0.00: TMA, DIPT, MDA, MDMA, mescaline, 5-MeO-TMT, EMDT, 5-MeO-DIPT, salvinorin A; ND: morphine, THC 5ht2c: 4.00 DOI, 3.42 DMT, 3.38 2C-E, 3.18 2C-B, 3.13 DOET, 3.11 LSD, 3.09 4C-T-2, 3.05 2C-T-2, 3.02 TMA, 2.97 DOB, 2.93 2C-B-fly, 2.58 TMA-2, 2.58 6-F-DMT, 2.52 psilocin, 2.50 Aleph-2, 2.34 cis-2a, 2.31 DPT, 2.17 5-MeO-TMT, 2.15 MDA, 2.03 SS-2c, 1.95 EMDT, 1.75 5-MeO-MIPT, 1.63 RR-2b, 1.55 5-MeO-DMT, 1.47 DOM; 0.00: 5-MeO-DIPT, mescaline, lisuride, MEM, MDMA, DIPT, ibogaine, salvinorin A; ND: morphine, THC Alpha2C: 4.00 mescaline, 3.88 lisuride, 3.60 MDA, 3.53 DMT, 3.44 2C-E, 3.24 6-F-DMT, 3.21 MDMA, 3.12 2C-B, 2.98 TMA, 2.88 DOI, 2.79 DPT, 2.68 DIPT, 2.66 5-MeO-DIPT, 2.56 2C-T-2, 2.29 5-MeO-MIPT, 2.10 DOM, 2.00 DOET, 1.82 DOB, 1.59 2C-B-fly, 1.57 5-MeO-DMT, 1.06 Aleph-2, 1.03 psilocin; 0.00: 4C-T-2, MEM, TMA-2; ND: LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC 5ht6: 4.00 6-F-DMT, 4.00 EMDT, 4.00 5-MeO-TMT, 3.75 LSD, 3.25 cis-2a, 3.25 DMT, 2.98 5-MeO-MIPT, 2.82 psilocin, 2.73 5-MeO-DMT, 2.63 2C-B, 2.61 lisuride, 2.52 RR-2b, 2.44 SS-2c, 2.34 DOI, 1.93 2C-E, 1.85 DPT, 1.78 2C-B-fly, 1.64 2C-T-2, 1.16 DOM, 0.85 DOB, 0.72 Aleph-2; 0.00: 4C-T-2, 5-MeO-DIPT, mescaline, TMA, TMA-2, MDA, DOET, MEM, MDMA, DIPT, salvinorin A; ND: ibogaine, morphine, THC 5ht1b: 4.00 LSD, 4.00 RR-2b, 3.79 cis-2a, 3.22 SS-2c, 3.22 TMA, 3.11 2C-B, 3.07 6-F-DMT, 3.00 2C-E, 2.61 5-MeO-MIPT, 2.57 DPT, 2.41 5-MeO-DIPT, 2.41 5-MeO-DMT, 2.27 lisuride, 2.19 psilocin, 1.84 2C-T-2, 1.71 DOET, 1.69 2C-B-fly, 1.62 DOB, 0.90 Aleph-2; 0.00: 4C-T-2, MDMA, mescaline, DMT, DIPT, TMA-2, DOM, MDA, DOI, MEM, ibogaine, salvinorin A; ND: 5-MeO-TMT, EMDT, morphine, THC 5ht1e: 3.28 DMT, 3.16 mescaline, 3.15 TMA, 3.05 2C-B, 3.03 psilocin, 2.74 6-F-DMT, 2.66 DOI, 2.62 LSD, 2.60 2C-E, 2.52 5-MeO-TMT, 2.49 EMDT, 2.16 2C-T-2, 2.16 RR-2b, 2.13 DPT, 2.07 cis-2a, 1.91 2C-B-fly, 1.83 lisuride, 1.77 4C-T-2, 1.72 5-MeO-DMT, 1.61 DOET, 1.55 5-MeO-MIPT, 1.52 DOM, 1.44 DOB, 1.16 SS-2c, 0.71 Aleph-2; 0.00: 5-MeO-DIPT, TMA-2, MDA, MEM, MDMA, DIPT, salvinorin A; ND: ibogaine, morphine, THC Alpha2A: 3.79 DOI, 3.36 TMA, 3.22 lisuride, 2.94 MDMA, 2.93 LSD, 2.92 mescaline, 2.85 5-MeO-MIPT, 2.84 DPT, 2.75 DMT, 2.74 MDA, 2.71 2C-E, 2.64 2C-B, 2.30 DOM, 2.05 DOET, 1.92 2C-T-2, 1.79 2C-B-fly, 1.36 psilocin, 1.00 5-MeO-DMT, 0.96 DOB, 0.44 Aleph-2; 0.00: 4C-T-2, DIPT, 5-MeO-DIPT, MEM, TMA-2, 6-F-DMT; ND: cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC Alpha2B: 3.78 lisuride, 3.53 DMT, 3.13 DOI, 3.12 MDA, 3.09 MDMA, 2.99 6-F-DMT, 2.97 DPT, 2.91 2C-E, 2.62 DIPT, 2.40 DOET, 2.40 5-MeO-DIPT, 2.31 2C-B, 2.13 DOM, 1.86 5-MeO-MIPT, 1.79 2C-T-2, 1.57 psilocin, 1.41 DOB, 1.16 2C-B-fly, 0.86 5-MeO-DMT, 0.74 Aleph-2; 0.00: 4C-T-2, mescaline, TMA, MEM, TMA-2; ND: LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC Imidazoline1: 4.00 MDMA, 3.53 DIPT, 3.44 mescaline, 3.24 5-MeO-DIPT, 3.13 DMT, 2.97 DPT, 2.79 4C-T-2, 2.45 6-F-DMT, 2.15 5-MeO-MIPT, 1.80 2C-B, 1.77 psilocin, 1.70 Aleph-2, 1.46 2C-T-2, 1.39 DOB, 0.88 5-MeO-DMT; 0.00: MEM, 2C-E, MDA, lisuride, DOI, 2C-B-fly, DOM, TMA, DOET; ND: TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC 5ht5a: 3.64 LSD, 3.20 RR-2b, 3.16 DMT, 3.15 cis-2a, 2.99 lisuride, 2.83 psilocin, 2.56 4C-T-2, 2.43 6-F-DMT, 2.17 SS-2c, 2.11 5-MeO-MIPT, 1.86 DPT, 1.84 5-MeO-DMT, 1.76 5-MeO-TMT, 1.54 EMDT, 0.87 DOB; 0.00: MDMA, 5-MeO-DIPT, 2C-B, MDA, mescaline, 2C-B-fly, DOI, TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, DOM, DIPT, salvinorin A; ND: ibogaine, morphine, THC D3: 3.46 cis-2a, 3.16 LSD, 2.82 SS-2c, 2.67 psilocin, 2.66 4C-T-2, 2.56 DIPT, 2.47 6-F-DMT, 2.40 RR-2b, 2.37 DPT, 2.27 2C-E, 1.70 5-MeO-MIPT, 1.68 DOB, 1.58 5-MeO-DMT, 1.51 2C-T-2, 1.47 ibogaine, 1.41 Aleph-2, 1.34 lisuride, 1.28 2C-B; 0.00: MDMA, mescaline, MEM, DMT, TMA, DOET, TMA-2, DOM, MDA, DOI, salvinorin A, 5-MeO-TMT, EMDT, 5-MeO-DIPT; ND: 2C-B-fly, morphine, THC Sigma1: 3.95 TMA, 3.05 4C-T-2, 2.90 DPT, 2.83 DIPT, 2.55 ibogaine, 2.23 DMT, 2.15 5-MeO-DIPT, 2.10 MEM, 1.83 Aleph-2, 1.73 DOI, 1.57 6-F-DMT, 1.25 DOB, 1.19 2C-T-2, 1.17 DOET; 0.00: 2C-B, mescaline, 5-MeO-MIPT, DOM, 2C-B-fly, 5-MeO-DMT, psilocin; ND: 2C-E, lisuride, MDA, TMA-2, LSD, cis-2a, MDMA, SS-2c, 5-MeO-TMT, EMDT, RR-2b, salvinorin A, morphine, THC SERT: 3.57 ibogaine, 3.31 DPT, 3.25 6-F-DMT, 2.98 DIPT, 2.83 DOI, 2.72 5-MeO-DIPT, 2.37 DMT, 1.74 psilocin, 1.28 5-MeO-MIPT, 1.08 Aleph-2, 0.97 5-MeO-DMT, 0.66 DOB; 0.00: 2C-E, MDA, 2C-B, mescaline, 4C-T-2, 2C-T-2, lisuride, MEM, 2C-B-fly, DOM, TMA, MDMA, TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, DOET, salvinorin A; ND: morphine, THC Beta2: 3.67 4C-T-2, 3.52 DOI, 3.38 DOM, 2.79 Aleph-2, 2.11 DOB, 1.93 lisuride, 1.82 DOET, 1.70 2C-T-2, 1.05 LSD, 0.70 cis-2a, 0.57 SS-2c; 0.00: 5-MeO-DMT, DMT, mescaline, DIPT, DPT, 5-MeO-MIPT, 6-F-DMT, 5-MeO-DIPT, MDMA, 2C-B-fly, psilocin, TMA, TMA-2, MDA, MEM, salvinorin A; ND: 2C-B, 2C-E, RR-2b, 5-MeO-TMT, ibogaine, EMDT, morphine, THC Sigma2: 4.00 ibogaine, 3.95 TMA, 2.65 DIPT, 2.64 5-MeO-DIPT, 2.13 5-MeO-MIPT, 2.04 DPT, 1.70 DOI, 1.56 6-F-DMT, 1.18 DOET; 0.00: 2C-T-2, 2C-E, mescaline, 2C-B, DOB, Aleph-2, MEM, 4C-T-2, DOM, DMT, 5-MeO-DMT, 2C-B-fly, psilocin; ND: lisuride, MDA, TMA-2, LSD, cis-2a, MDMA, SS-2c, 5-MeO-TMT, EMDT, RR-2b, salvinorin A, morphine, THC H1: 3.74 6-F-DMT, 3.41 DPT, 3.04 TMA-2, 2.53 DIPT, 2.42 DOI, 1.66 cis-2a, 1.41 5-MeO-MIPT, 1.40 LSD, 1.14 RR-2b, 0.63 DOB, 0.20 SS-2c, 0.19 2C-B-fly; 0.00: psilocin, 2C-B, 5-MeO-DIPT, TMA, 4C-T-2, 2C-E, 2C-T-2, MDMA, mescaline, DOM, EMDT, DOET, salvinorin A, 5-MeO-TMT, MEM, Aleph-2, ibogaine; ND: lisuride, DMT, MDA, 5-MeO-DMT, morphine, THC D1: 3.51 DMT, 3.37 psilocin, 2.67 6-F-DMT, 2.38 5-MeO-DMT, 2.34 LSD, 2.00 cis-2a, 1.77 RR-2b, 1.67 DOI, 1.14 SS-2c, 0.26 2C-B-fly; 0.00: 2C-B, MDA, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, lisuride, MDMA, mescaline, DOM, TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-TMT, EMDT, ibogaine, salvinorin A; ND: morphine, THC D2: 2.67 cis-2a, 2.65 lisuride, 2.62 6-F-DMT, 2.55 LSD, 1.88 RR-2b, 1.88 2C-E, 1.74 SS-2c, 1.60 2C-B, 1.54 DPT, 1.33 2C-T-2, 0.73 5-MeO-DMT, 0.12 2C-B-fly; 0.00: psilocin, 5-MeO-MIPT, 5-MeO-DIPT, DMT, 4C-T-2, DIPT, MDMA, DOI, mescaline, DOM, TMA, DOET, TMA-2, DOB, MDA, Aleph-2, MEM, 5-MeO-TMT, EMDT, ibogaine, salvinorin A; ND: morphine, THC D4: 2.90 lisuride, 2.49 cis-2a, 2.39 LSD, 2.25 6-F-DMT, 2.20 DPT, 2.08 RR-2b, 1.62 SS-2c, 1.29 5-MeO-MIPT, 0.78 5-MeO-DMT; 0.00: psilocin, MDMA, DMT, 2C-B, DIPT, 5-MeO-DIPT, mescaline, 4C-T-2, DOB, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-TMT, EMDT, salvinorin A; ND: ibogaine, morphine, THC M3: 3.07 MDMA, 2.51 DOI, 2.22 2C-B, 2.22 ibogaine, 1.99 2C-E, 1.94 2C-T-2, 1.53 DOB, 1.42 2C-B-fly, 0.92 Aleph-2; 0.00: DMT, lisuride, 5-MeO-DMT, 5-MeO-MIPT, DIPT, psilocin, DPT, 4C-T-2, 6-F-DMT, mescaline, MEM, salvinorin A, 5-MeO-DIPT; ND: MDA, DOM, TMA, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, DOET, TMA-2, morphine, THC Alpha1A: 3.17 6-F-DMT, 2.70 DMT, 2.56 DPT, 2.09 lisuride, 1.64 cis-2a, 1.56 DOM, 1.54 LSD, 0.67 SS-2c, 0.59 RR-2b; 0.00: psilocin, MDMA, mescaline, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, 5-MeO-DMT, 4C-T-2, DOB, MDA, DOI, 2C-B-fly, 2C-B, TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, salvinorin A; ND: 5-MeO-TMT, ibogaine, EMDT, morphine, THC KOR: 4.00 salvinorin A, 2.88 ibogaine, 2.21 morphine; 0.00: MDA, 2C-B, DMT, MDMA, mescaline, DOB, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, psilocin, 5-MeO-DMT, 2C-E, LSD, lisuride, DOI, 2C-B-fly, DOM, TMA, DOET, DPT, 4C-T-2, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, 5-MeO-DIPT; ND: TMA-2, 6-F-DMT, THC Beta1: 2.89 DOI, 2.56 lisuride, 1.76 cis-2a, 1.72 SS-2c, 1.40 DOET, 1.39 LSD, 1.21 DOB, 0.81 2C-T-2, 0.37 Aleph-2; 0.00: 5-MeO-DMT, DMT, mescaline, DOM, DIPT, 5-MeO-MIPT, DPT, 4C-T-2, 6-F-DMT, 5-MeO-DIPT, MDMA, 2C-B-fly, 2C-E, TMA, psilocin, TMA-2, ibogaine, MDA, MEM, salvinorin A; ND: 2C-B, 5-MeO-TMT, RR-2b, EMDT, morphine, THC MOR: 4.00 morphine, 2.67 ibogaine; 0.00: lisuride, mescaline, 2C-B, TMA, MDMA, DPT, DOB, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, psilocin, DOET, 2C-E, LSD, cis-2a, DOI, 2C-B-fly, DOM, EMDT, 5-MeO-DIPT, salvinorin A, 4C-T-2, SS-2c, RR-2b, 5-MeO-TMT; ND: MDA, DMT, 5-MeO-DMT, TMA-2, 6-F-DMT, THC M5: 2.54 MDMA, 2.32 DOI, 2.16 2C-E, 1.60 2C-T-2, 1.01 2C-B-fly, 0.30 Aleph-2; 0.00: 2C-B, DMT, DOB, MDA, DOET, 5-MeO-DMT, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, 6-F-DMT, lisuride, MEM, mescaline, DOM, TMA, TMA-2, salvinorin A; ND: psilocin, LSD, RR-2b, cis-2a, 5-MeO-TMT, EMDT, ibogaine, SS-2c, morphine, THC Alpha1B: 2.95 DMT, 2.86 DPT, 1.08 lisuride, 0.65 LSD; 0.00: MDMA, 2C-B, psilocin, mescaline, DOB, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, 5-MeO-DMT, 4C-T-2, 6-F-DMT, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, 2C-E, cis-2a, RR-2b, SS-2c, salvinorin A; ND: 5-MeO-TMT, ibogaine, EMDT, morphine, THC CB1: 4.00 THC; 0.00: MDA, MDMA, mescaline, 2C-B, DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 2C-B-fly, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, lisuride, DOI, TMA, DOM, 6-F-DMT, DOET; ND: 5-MeO-MIPT, LSD, TMA-2, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, cis-2a M4: 2.90 DOI, 2.43 MDMA, 1.24 2C-B-fly; 0.00: DOB, 2C-B, lisuride, psilocin, DMT, 2C-E, 2C-T-2, Aleph-2, 5-MeO-DMT, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, 6-F-DMT, mescaline, MEM, salvinorin A; ND: DOM, MDA, DOET, TMA, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, TMA-2, morphine, THC DAT: 3.02 ibogaine, 2.33 DPT; 0.00: DOB, MDA, 2C-B, DMT, MDMA, mescaline, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, psilocin, 5-MeO-DMT, 4C-T-2, 6-F-DMT, lisuride, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, 5-MeO-DIPT, salvinorin A; ND: morphine, THC D5: 2.05 LSD, 1.61 6-F-DMT, 1.59 lisuride, 1.53 RR-2b, 1.36 cis-2a, 1.00 SS-2c; 0.00: psilocin, 5-MeO-DMT, 2C-B, DMT, MDMA, mescaline, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-TMT, EMDT, salvinorin A; ND: ibogaine, morphine, THC CB2: 3.78 THC; 0.00: MDA, DOI, mescaline, 2C-B, DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, lisuride, DOET, 2C-B-fly, DOM, TMA, 6-F-DMT; ND: MDMA, LSD, TMA-2, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, cis-2a Ca+Channel: 3.26 MDMA; 0.00: lisuride, DOB, mescaline, 5-MeO-MIPT, DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 4C-T-2, DIPT, 5-MeO-DIPT, DPT, 6-F-DMT; ND: 2C-B, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, ibogaine, salvinorin A, morphine, THC M1: 2.23 DOI, 1.96 ibogaine, 1.15 2C-B-fly; 0.00: lisuride, DOB, DMT, 2C-B, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, psilocin, DPT, 4C-T-2, 6-F-DMT, mescaline, MDMA, salvinorin A, DOM, 5-MeO-DIPT; ND: MDA, TMA, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, DOET, TMA-2, morphine, THC NMDA: 3.01 ibogaine; 0.00: 2C-T-2, DOB, mescaline, 2C-B, TMA, MDMA, DPT, 2C-E, 6-F-DMT, Aleph-2, MEM, 5-MeO-MIPT, DIPT, DOET, 5-MeO-DIPT, 4C-T-2, DOM, DOI; ND: lisuride, 2C-B-fly, MDA, DMT, 5-MeO-DMT, TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-TMT, EMDT, psilocin, salvinorin A, morphine, THC M2: 2.36 DOI, 1.72 ibogaine, 0.65 2C-B-fly; 0.00: MDA, DOB, DMT, 2C-B, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, psilocin, DPT, 4C-T-2, 6-F-DMT, lisuride, MDMA, mescaline, DOM, TMA, DOET, TMA-2, 5-MeO-DIPT, salvinorin A; ND: LSD, cis-2a, 5-MeO-TMT, EMDT, RR-2b, SS-2c, morphine, THC H2: 2.44 6-F-DMT, 1.42 lisuride; 0.00: MDMA, mescaline, 2C-B, DMT, psilocin, 5-MeO-DMT, 2C-E, 2C-T-2, Aleph-2, MEM, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, DOB, MDA, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, 5-MeO-TMT, EMDT; ND: RR-2b, SS-2c, LSD, cis-2a, ibogaine, salvinorin A, morphine, THC NET: 1.97 5-MeO-TMT, 0.82 5-MeO-DMT; 0.00: MDMA, MDA, DOB, DMT, psilocin, mescaline, 2C-E, 2C-T-2, Aleph-2, MEM, 2C-B, DIPT, 5-MeO-DIPT, DPT, 4C-T-2, 6-F-DMT, lisuride, DOI, 2C-B-fly, DOM, TMA, DOET, TMA-2, LSD, cis-2a, RR-2b, SS-2c, 5-MeO-MIPT, EMDT; ND: ibogaine, salvinorin A, morphine, THC DOR: 0.72 morphine; 0.00: 2C-T-2, DOI, mescaline, 2C-B, TMA, psilocin, DPT, DOB, LSD, Aleph-2, MEM, 5-MeO-MIPT, DIPT, 5-MeO-DIPT, DOET, 2C-E, 4C-T-2, cis-2a, RR-2b, 2C-B-fly, DOM, EMDT, ibogaine, salvinorin A, 5-MeO-TMT, SS-2c; ND: MDMA, lisuride, MDA, DMT, 5-MeO-DMT, TMA-2, 6-F-DMT, THC TABLE: Forty-two receptors arranged in order of decreasing interaction with the full set of thirty-five drugs. B Receptor B sq Receptor B exp Receptor 102.400 5ht2b 19.479 5ht2b 7.094 5ht2b 82.564 5ht1a 16.634 5ht1a 6.709 5ht1a 75.736 5ht7 14.931 5ht7 6.348 5ht7 66.217 5ht1d 14.574 5ht1d 6.348 5ht1d 65.462 5ht2a 13.806 5ht2a 6.153 5ht2a 64.798 5ht2c 13.352 5ht2c 6.071 Alpha2C 58.020 Alpha2C 12.989 Alpha2C 6.037 5ht2c 55.055 5ht1e 12.430 5ht6 6.034 5ht6 53.236 5ht6 11.951 5ht1b 5.930 5ht1b 49.634 5ht1b 11.508 5ht1e 5.722 Alpha2A 47.526 Alpha2A 11.304 Alpha2A 5.709 Alpha2B 46.760 Alpha2B 11.138 Alpha2B 5.666 5ht1e 38.823 D3 10.097 Imidazoline1 5.608 Imidazoline1 36.702 Imidazoline1 9.741 5ht5a 5.450 5ht5a 36.079 5ht5a 9.561 D3 5.348 D3 30.487 Sigma1 8.657 Sigma1 5.271 Sigma1 26.764 SERT 8.448 SERT 5.252 SERT 23.237 Beta2 7.831 Beta2 5.248 Sigma2 21.839 Sigma2 7.808 Sigma2 5.170 Beta2 21.769 H1 7.452 H1 5.080 H1 21.302 D2 7.296 D1 4.985 D1 21.107 D1 6.697 D2 4.732 D2 17.995 D4 6.278 D4 4.732 KOR 17.821 M3 6.205 M3 4.649 D4 16.510 Alpha1A 6.043 Alpha1A 4.644 Alpha1A 14.117 Beta1 5.401 KOR 4.643 M3 9.935 M5 5.209 Beta1 4.626 MOR 9.137 D5 4.812 MOR 4.484 CB1 9.089 KOR 4.492 M5 4.425 Beta1 7.540 Alpha1B 4.297 Alpha1B 4.355 CB2 6.674 MOR 4.000 CB1 4.282 Alpha1B 6.563 M4 3.978 M4 4.243 M5 5.344 DAT 3.810 DAT 4.173 M4 5.334 M1 3.809 D5 4.154 DAT 4.727 M2 3.782 CB2 4.097 Ca+Channel 4.000 CB1 3.263 Ca+Channel 4.059 D5 3.861 H2 3.181 M1 3.995 NMDA 3.783 CB2 3.013 NMDA 3.942 M1 3.263 Ca+Channel 2.992 M2 3.914 M2 3.013 NMDA 2.824 H2 3.884 H2 2.796 NET 2.138 NET 3.749 NET 0.720 DOR 0.720 DOR 3.585 DOR ACTIVITY DATA The NIMH-PDSP provided activity data for the twenty-five drugs of Fig. 1 , for 5-HT 2A and 5-HT 2C ( Table S3 ). While most compounds appear to be full agonists at the two receptors, there are a few exceptions. Lower values of activity were reported for psilocin, MDMA, DOM and the three control drugs: 4C-T-2, 6-fluoro-DMT, and lisuride. DISCUSSION Perhaps the most striking result of the NIMH-PDSP assays has been to show that the psychedelics interact with a large number of receptors (forty-two of the forty-nine sites at which most of the drugs were assayed). While the phenylalkylamines tend to be more selective than the tryptamines and ergolines, they generally can not be accurately characterized as selective for 5-HT 2 , as they are so widely described in the literature [1] , [4] , [6] , [7] , [14] , [15] . Only DOB and MEM come close to fitting that description. Ironically, DOI has been one of the drugs of choice in studies of the molecular pharmacology of psychedelics, and has been widely assumed to be a 5-HT 2 -selective agent [4] , [6] , [7] , [15] , [16] . This study has revealed DOI to be one of the least selective of all psychedelics. Some of the literature on DOI may need to be reinterpreted. The same may be true of any studies whose conclusions rely on the assumption that psychedelics are selective. Studies requiring drugs selective for 5-HT 2 should be conducted with DOB or MEM, and they should not be presented as typical or characteristic of psychedelics. In addition to showing that psychedelics are not as selective as generally believed, the data presented also shows that they exhibit diverse patterns of receptor interactions. Different drugs emphasize different classes of receptors. 5-HT 2B is the best hit for thirteen drugs, and 5-HT 1A is the best hit for nine drugs. Five of the top six psychedelic receptors ( Table 5 ) are 5-HT 1 and 5-HT 2 receptors. If we acknowledge the pervasiveness of the 5-HT 1 and 5-HT 2 receptors, and then look past them, we find that the set of thirty-five drugs emphasize a wide variety of receptors: 5-HT 1A  DOET 5-HT 1D  2C-B-fly 5-HT 2  DOB, 2C-T-2 5-HT 2B  MEM 5-HT 5A  RR-2b 5-HT 6  EMDT , 5-MeO-TMT , 6-F-DMT 5-HT 7  DMT , 5-MeO-MIPT , LSD , 5-MeO-DMT α 2A  DOI α 2C  mescaline , lisuride , MDA , 2C-E β 2  DOM , 2C-B , Aleph-2 , 4C-T-2 H 1  TMA-2 , DPT σ 2  ibogaine , TMA D 1  psilocin D 3  cis-2a , SS-2c I 1  MDMA , DIPT , 5-MeO-DIPT κ salvinorin A μ morphine CB 1  THC It should be possible to use this diverse set of drugs as probes into the roles played by the various receptor systems in the human mind. In the papers that follow, this possibility will be explored by synthesizing the NIMH-PDSP data together with the data on the human pharmacology of these drugs. SUPPORTING INFORMATION Receptor affinity profiles of psychedelic drugs, ordered by receptor type. The vertical axis is normalized pKi (npKi). Horizontal axis is a list of forty-two receptors, grouped by receptor type. The drugs are ordered to correspond roughly to similarity of structure and receptor affinity profiles. Colors correspond to classes of receptors. It can be seen at a glance that most, but not all of the drugs interact strongly with the serotonin receptors (beige), certain drugs interact strongly with the dopamine receptors (red), others with the adrenergic receptors (green), yet others with the histamine receptors (yellow), etc. (0.14 MB DOC) Receptor affinity profiles of psychedelic drugs, ordered by decreasing affinity. The vertical axis is normalized pKi (npKi). Horizontal axis is a list of forty-two receptors, arranged in order of decreasing affinity for each individual drug. The thirty-five drugs are arranged in order of decreasing breadth, based on the Bsq values of Table 3 and Fig. 4 . Drugs at the top of the figure have the broadest receptor interactions (least selective), while drugs at the bottom of the figure have the narrowest receptor interactions (most selective). Colors correspond to classes of receptors, and are the same as used in Fig. S1 . The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity. As a rule of thumb, this is presumed to be the limit of perceptible receptor interaction. Receptors to the right of the black bar should be imperceptible, while receptors to the left of the black bar should be perceptible, increasingly so the further left they are. (0.18 MB DOC) Receptor affinities at forty-two receptors across thirty-five drugs, ordered by decreasing breadth of receptor. The vertical axis is normalized pKi (npKi). Horizontal axis is a list of thirty-five drugs, ordered by decreasing affinity at the receptor. The forty-two receptors are arranged in order of decreasing breadth, based on the Bsq values of Table 5 and Fig. 5 . Receptors at the top of the figure have the broadest interactions with the thirty-five drugs, while receptors at the bottom of the figure have the narrowest interactions with the thirty-five drugs. The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity at each drug. As a rule of thumb, this is presumed to be the limit of perceptible receptor interaction. Drugs to the right of the black bar should have imperceptible interactions with the receptor, while drugs to the left of the black bar should have perceptible interactions with the receptor, increasingly so the further left they are. (0.20 MB DOC) Receptor affinity data for ibogaine. Table S1 reports receptor affinity data for ibogaine collected from the literature. The columns identify the receptor, the species from which the receptor was used, the tissue from which the receptor was used, the radioligand used in determining affinity, the Ki value in nanomoles or the IC50 value in nanomoles, and the literature reference from which the data was obtained. (0.31 MB DOC) Raw affinity (Ki) data for thirty-five drugs at sixty-seven sites. The table has been divided into three sections. The first section displays forty-two sites at which most compounds were assayed and at least one “hit” (Ki<10,000 nm) was found (5ht1a, 5ht1b, 5ht1d, 5ht1e, 5ht2a, 5ht2b, 5ht2c, 5ht5a, 5ht6, 5ht7, D1, D2, D3, D4, D5, Alpha1A, Alpha1B, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, SERT, DAT, NET, Imidazoline1, Sigma1, Sigma2, DOR, KOR, MOR, M1, M2, M3, M4, M5, H1, H2, CB1, CB2, Ca+Channel, NMDA/MK801). The second section displays seven sites at which most compounds were assayed, but at which there were no hits (5ht3, H3, H4, V1, V2, V3, GabaA). The third section displays the remaining eighteen sites, at which only a few compounds were assayed, and no hits were found (GabaB, mGluR1a, mGluR2, mGluR4, mGluR5, mGluR6, mGluR8, A2B2, A2B4, A3B2, A3B4, A4B2, A4B2**, A4B4, BZP (a1), EP3, MDR 1, PCP). Missing Ki values are indicated by “ND” meaning that no data is available, or by “PH” meaning that the primary assay “hit” (>50% inhibition), but the secondary assay was not performed. For the first section of the table, an extra row and column labeled “ND/PH” provides a count of missing Ki data in the two categories, for each compound and for each receptor. (0.05 MB XLS) Activity data for twenty-five drugs at 5-HT2A and 5-HT2C. GF62 is the cell line that expresses the 5-HT2A receptor, and INI is the cell line that expresses the 5-HT2C receptor. The “EC50 nM” columns express the concentration that gives half of the maximal activity for that drug. The maximal activity is displayed in the “Emax±SEM” column, and represent Ca++ mobilization relative to 5-HT which should give an Emax value of 100%. Data for the drugs should produce lower Emax values. For a compound that gives, for example, 53% Emax, the EC50 is the concentration where 26.5% response occurs. Emax values above 100%±SEM are an artifact caused by extrapolation by the graphpad program when it doesn't have points at the top end to define the asymptote. The data represent the mean ± variance of computer-derived estimates from single experiments done in quadruplicate. Thus, the four observations are averaged and a single estimate with error is provided. (0.13 MB DOC) Affinity (Ki) data transformed into pKi values for thirty-five drugs at forty-two sites. Table S4 presents the raw Ki data transformed into pKi values. Higher affinities produce lower Ki values, thus it is valuable to calculate: pKi = −log10(Ki). Higher affinities have higher pKi values, and each unit of pKi value corresponds to one order of magnitude of Ki value. ND means the data is not available, and UM means that Ki was measured as >10,000 nm. Generally, the highest Ki value generated by NIMH-PDSP is 10,000, which produces a pKi value of −4 (although a value of 10,450 was reported for 5-MeO-TMT). For non-PDSP data gathered from the literature, some values greater than 10,000 are reported (i.e. 12,500, 14,142, 22,486, 39,409 and 70,000 for ibogaine). (0.04 MB XLS) Thirty-five drugs arranged in order of decreasing breadth at selected groups of receptors. The thirty-five drugs are arranged in order of decreasing breadth at groups of receptors, based on the breadth index Bsq. The drugs with the broadest receptor interactions within the group are found at the tops of the columns, and the drugs with the least receptor interactions are found at the bottoms of the columns. Some columns list the maximum npKi value for a group of receptors (e.g. 5-HT2max). In this example, the column lists the highest npKi value of the three 5-HT2 receptors (5-HT2A, 5-HT2B, and 5-HT2C). An entry of “ND” indicates that the statistic could not be calculated because some data is missing. For example, to calculate Bsq for 5-HT2, or npKi for 5-HT2max, we need npKi values for 5-HT2A, 5-HT2B, and 5-HT2C. If any one of the three values is missing, the statistics will be reported as ND. Values of 0.00 correspond to Ki values of >10,000. The same data is also presented in Table S6 Receptors in a group are listed in the column heading, or are represented with the following abbreviations: • 5-HT - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7 • 5-HT2 - 5-HT2A, 5-HT2B, 5-HT2C • 5-HT2max - maximum of 5-HT2A, 5-HT2B, 5-HT2C • 5-HT2A/Cmax - maximum of 5-HT2A, 5-HT2C • 5-HT1 - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E • 5-HT1max - maximum of 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E • Dmax - maximum of D1, D2, D3, D4, D5 • Adrenergic - α1A, α1B, α2A, α2B, α2C, β1, β2 • AdrenergicMax - maximum of α1A, α1B, α2A, α2B, α2C, β1, β2 • α1max - maximum of α1A, α1B • α2max - maximum of α2A, α2B, α2C • βmax - maximum of β1, β2 • Hmax - maximum of H1, H2 • σmax - maximum of σ1, σ 2 • Mmax - maximum of M1, M2, M3, M4, M5 • TransportersMax - maximum of SERT, DAT, NET • OpioidMax - maximum of DOR, KOR, MOR (0.61 MB DOC) Table of npKi, Bsq, or npKimax values at individual or groups of receptors for thirty-five drugs. Table S6 presents the normalized pKi data (npKi) for thirty five drugs at forty-two receptors, transporters and ion channels. In addition, it presents the three breadth statistics (B, Bsq, Bexp) for each drug across all forty-two sites, the breadth statistic Bsq for sixteen groups of related sites, and the maximum npKi value for thirteen groups of related sites. A useful way to work with the table is to choose a column, and sort the data on that column (click “Data, “Sort,” select “Header row,” choose the column from the “Sort by” drop down and select “Descending,” finally clicking “OK”). Missing values are reported as “ND.” Values of 0.0000 correspond to Ki values of >10,000. Receptors in a group are listed in the column headings using the following abbreviations: • B - sum of npKi values across forty-two receptors • Bsq - square root of sum of squares of npKi values across forty-two receptors • Bexp - log of sum of exponents of npKi values across forty-two receptors • 5ht - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7 • 5ht1 - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E • 5ht1max - maximum of 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E • 5ht2 - 5-HT2A, 5-HT2B, 5-HT2C • 5ht2max - maximum of 5-HT2A, 5-HT2B, 5-HT2C • 5ht2[ac] - 5-HT2A, 5-HT2C • 5ht2[ac]max - maximum of 5-HT2A, 5-HT2C • 5ht[67] - 5-HT6, 5-HT7 • D[1–5] - D1, D2, D3, D4, D5 • D[1–5]max - maximum of D1, D2, D3, D4, D5 • ∧[AB] - α1A, α1B, α2A, α2B, α2C, β1, β2 • ∧[AB]max - maximum of α1A, α1B, α2A, α2B, α2C, β1, β2 • Alpha1 - α1A, α1B • Alpha1max - maximum of α1A, α1B • Alpha2 - α2A, α2B, α2C • Alpha2max - maximum of α2A, α2B, α2C • Beta - β1, β2 • BetaMax - maximum of β1, β2 • M[1–5] - M1, M2, M3, M4, M5 • M[1–5]max - maximum of M1, M2, M3, M4, M5 • Sigma - σ1, σ 2 • SigmaMax - maximum of σ1, σ 2 • H[12] - H1, H2 • H[1–2]max - maximum of H1, H2 • T$ - SERT, DAT, NET • T$max - maximum of SERT, DAT, NET • [DKM]OR - DOR, KOR, MOR • [DKM]ORmax - maximum of DOR, KOR, MOR • CB[12] - CB1, CB2 (0.05 MB XLS) Thirty-five drugs arranged in order of decreasing proportional interaction at selected groups of receptors. The thirty-five drugs are arranged in order of decreasing proportional interaction at groups of receptors, based on the proportional breadth index Bp. The drugs with the greatest proportional interactions are found at the tops of the columns, and the drugs with the least proportional interactions are found at the bottoms of the columns. An entry of “ND” indicates that the statistic could not be calculated because some data is missing. The same data is also presented in Table S8 . Receptors in a group are listed in the column heading, or are represented with the following abbreviations: • 5-HT - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7 • 5-HT1 - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E • Adrenergic - α1A, α1B, α2A, α2B, α2C, β1, β2 (0.37 MB DOC) Table of Bp values at individual or groups of receptors for thirty-five drugs. Table S8 presents the proportional breadth statistic Bp for each drug at each of forty-two sites, and for sixteen groups of related sites. A useful way to work with the table is to choose a column, and sort the data on that column (click “Data, “Sort,” select “Header row,” choose the column from the “Sort by” drop down and select “Descending,” finally clicking “OK”). Missing values are reported as “ND.” Receptors in a group are listed in the column headings using the following abbreviations: • Bsq - square root of sum of squares of npKi values across forty-two receptors • 5ht - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7 • 5ht1 - 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E • 5ht2 - 5-HT2A, 5-HT2B, 5-HT2C • 5ht2[ac] - 5-HT2A, 5-HT2C • 5ht[67] - 5-HT6, 5-HT7 • D[1–5] - D1, D2, D3, D4, D5 • ∧[AB] - α1A, α1B, α2A, α2B, α2C, β1, β2 • Alpha1 - α1A, α1B • Alpha2 - α2A, α2B, α2C • Beta - β1, β2 • M[1–5] - M1, M2, M3, M4, M5 • Sigma - σ1, σ 2 • H[12] - H1, H2 • T$ - SERT, DAT, NET • [DKM]OR - DOR, KOR, MOR • CB[12] - CB1, CB2 (0.04 MB XLS) REFERENCES [1] Nichols DE 2004 Hallucinogens. Pharmacology & Therapeutics 101 131 81 [2] Glennon RA Young R Rosecrans JA 1983 Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91 189 96 [3] Glennon RA Titeler M McKenney JD 1984 Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences 35 2505 11 [4] Glennon RA Titeler M Young R 1986 Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull 22 953 8 [5] Glennon RA Darmani NA Martin BR 1991 Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci 48 2493 8 [6] Glennon RA 1990 Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 3 509 17 [7] Glennon R 1996 Classic Hallucinogens. Handbook of Experimental Pharmacology 118 343 71 [8] Blair JB Kurrasch-Orbaugh D Marona-Lewicka D Cumbay MG Watts VJ 2000 Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 43 4701 10 [9] Nichols DE 1986 Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18 305 13 [10] Nichols DE Frescas S Marona-Lewicka D Kurrasch-Orbaugh DM 2002 Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). Journal of Medicinal Chemistry 45 4344 9 [11] Roth BL Baner K Westkaemper R Siebert D Rice KC 2002 Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99 11934 9 [12] Glennon RA Lee M Rangisetty JB Dukat M Roth BL 2000 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. Journal of Medicinal Chemistry 43 1011 8 [13] Nichols DE Nichols CD 2008 Serotonin receptors. Chem Rev 108 1614 41 [14] Darmani NA 1992 Further evidence for enigmas in adaptation mechanisms for the DOI-induced behaviors. Pharmacol Biochem Behav 43 765 70 [15] Darmani NA Mock OB Towns LC Gerdes CF 1994 The head-twitch response in the least shrew (Cryptotis parva) is a 5-HT2- and not a 5-HT1C-mediated phenomenon. Pharmacol Biochem Behav 48 383 96 [16] Glennon RA Dukat M 1991 Serotonin receptors and their ligands: a lack of selective agents. Pharmacol Biochem Behav 40 1009 17 [17] Schiller PW Nguyen TM Berezowska I Dupuis S Weltrowska G 2000 Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur J Med Chem 35 895 901 [18] Valenzano KJ Miller W Chen Z Shan S Crumley G 2004 DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-a cetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. J Pharmacol Exp Ther 310 783 92 [19] Zhao GM Qian X Schiller PW Szeto HH 2003 Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. J Pharmacol Exp Ther 307 947 54 [20] Spetea M Toth F Schutz J Otvos F Toth G 2003 Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur J Neurosci 18 290 5 [21] Gharagozlou P Demirci H David CJ Lameh J 2003 Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 3 1 [22] Standifer KM Cheng J Brooks AI Honrado CP Su W 1994 Biochemical and pharmacological characterization of mu, delta and kappa 3 opioid receptors expressed in BE(2)-C neuroblastoma cells. J Pharmacol Exp Ther 270 1246 55 [23] Castanas E Bourhim N Giraud P Boudouresque F Cantau P 1985 Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I. Interaction with delta and mu sites. J Neurochem 45 677 87 [24] Clark JA Houghten R Pasternak GW 1988 Opiate binding in calf thalamic membranes: a selective mu 1 binding assay. Mol Pharmacol 34 308 17 [25] Wolozin BL Pasternak GW 1981 Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A 78 6181 5 [26] Neubig RR Spedding M Kenakin T Christopoulos A 2003 International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55 597 606 [27] De VJ Denzer D Reissmueller E Eijckenboom M Heil M 2004 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther 310 620 32 [28] Mauler F Mittendorf J Horvath E De VJ 2002 Characterization of the diarylether sulfonylester (−)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302 359 68 [29] Iwamura H Suzuki H Ueda Y Kaya T Inaba T 2001 In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296 420 5 [30] Griffin G Tao Q Abood ME 2000 Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292 886 94 [31] Largent BL Gundlach AL Snyder SH 1984 Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc Natl Acad Sci U S A 81 4983 7